Browse by UCL Department: listings for include files
- UCL (198993)
- UCL (198993)
- Provost and Vice Provost Offices (197752)
- School of Life and Medical Sciences (96774)
- Faculty of Medical Sciences (21915)
- Cancer Institute (4089)
- CRUK Cancer Trials Centre (452)
- Cancer Institute (4089)
- Faculty of Medical Sciences (21915)
- School of Life and Medical Sciences (96774)
- Provost and Vice Provost Offices (197752)
- UCL (198993)
Number of items at this level: 452.
A
Abbosh, C;
Hodgson, D;
Doherty, GJ;
Gale, D;
Black, JRM;
Horn, L;
Reis-Filho, JS;
(2024)
Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer.
Trends in Cancer
, 10
(7)
pp. 643-654.
10.1016/j.trecan.2024.04.004.
|
 |
|
Abbosh, Christopher;
Frankell, Alexander M;
Harrison, Thomas;
Kisistok, Judit;
Garnett, Aaron;
Johnson, Laura;
Veeriah, Selvaraju;
... Swanton, Charles; + view all
(2023)
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA.
Nature
, 616
(7957)
pp. 553-562.
10.1038/s41586-023-05776-4.
|
|
Abbosh, C;
Birkbak, NJ;
Wilson, GA;
Jamal-Hanjani, M;
Constantin, T;
Salari, R;
Le Quesne, J;
... Dessimoz, C; + view all
(2017)
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
Nature
, 545
pp. 446-451.
10.1038/nature22364.
|
|
AbdulJabbar, K;
Raza, SEA;
Rosenthal, R;
Jamal-Hanjani, M;
Veeriah, S;
Akarca, A;
Lund, T;
... Yuan, Y; + view all
(2020)
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma.
Nature Medicine
, 26
pp. 1054-1062.
10.1038/s41591-020-0900-x.
|
|
Ahern, A;
Griffin, S;
Wheeler, G;
Sharp, S;
Aveyard, P;
Boyland, E;
Halford, J;
(2020)
The effect of referral to an open-group behavioural weight management programme on the relative risk of normoglycaemia, non-diabetic hyperglycaemia and type 2 diabetes: secondary analysis of the WRAP trial.
Diabetes, Obesity and Metabolism
, 22
(11)
pp. 2069-2076.
10.1111/dom.14123.
|
|
|
Ahern, AL;
Wheeler, GM;
Aveyard, P;
Boyland, EJ;
Halford, JCG;
Mander, AP;
Woolston, J;
... Jebb, SA; + view all
(2017)
Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial.
The Lancet
, 389
(10085)
pp. 2214-2225.
10.1016/S0140-6736(17)30647-5.
|
|
|
Ainley, L;
Chavda, SJ;
Counsell, N;
Cheesman, S;
Newrick, F;
Horder, J;
Kyriakou, C;
... Yong, K; + view all
(2021)
DT‐PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation.
British Journal of Haematology
, 192
(3)
e73-e77.
10.1111/bjh.17248.
|
|
Al Bakir, Maise;
Huebner, Ariana;
Martínez-Ruiz, Carlos;
Grigoriadis, Kristiana;
Watkins, Thomas BK;
Pich, Oriol;
Moore, David A;
... Swanton, Charles; + view all
(2023)
The evolution of non-small cell lung cancer metastases in TRACERx.
Nature
10.1038/s41586-023-05729-x.
(In press).
|
|
Alberro, JA;
Ballester, B;
Deulofeu, P;
Fabregas, R;
Fraile, M;
Gubern, JM;
Janer, J;
... Llombart, HA; + view all
(2018)
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.
The Lancet Oncology
, 19
(1)
pp. 27-39.
10.1016/S1470-2045(17)30777-5.
|
|
|
Anderson, A;
Visintin, C;
Antoniou, A;
Pashayan, N;
Gilbert, FJ;
Hackshaw, A;
Bhatt, R;
... Given-Wilson, R; + view all
(2024)
Risk stratification in breast screening workshop.
BMC Proceedings
, 18
(Suppl 19)
, Article 22. 10.1186/s12919-024-00306-0.
|
|
Anderson, RA;
Remedios, R;
Kirkwood, AA;
Patrick, P;
Stevens, L;
Clifton-Hadley, L;
Roberts, T;
... Johnson, PWM; + view all
(2018)
Determinants of Ovarian Function After Response-adapted Therapy in Patients With Advanced Hodgkin's Lymphoma (RATHL): a Secondary Analysis of a Randomised Phase 3 Trial.
Lancet Oncology
, 19
(10)
pp. 1328-1337.
10.1016/S1470-2045(18)30500-X.
|
|
|
Angelis, A;
Naci, H;
Hackshaw, A;
(2020)
Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies.
Pharmacoeconomics
, 38
pp. 1297-1308.
10.1007/s40273-020-00956-w.
|
|
Arend, RC;
Monk, BJ;
Herzog, TJ;
Moore, KN;
Shapira-Frommer, R;
Ledermann, JA;
Tewari, KS;
... Penson, RT; + view all
(2021)
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer.
Gynecologic Oncology
, 161
(2)
pp. 496-501.
10.1016/j.ygyno.2021.02.014.
|
|
Au, L;
Hatipoglu, E;
Robert de Massy, M;
Litchfield, K;
Beattie, G;
Rowan, A;
Schnidrig, D;
... TRACERx Renal Consortium; + view all
(2021)
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
Cancer Cell
, 39
pp. 1497-1518.
10.1016/j.ccell.2021.10.001.
|
|
B
|
Bachy, E;
Rufibach, K;
Parreira, J;
Launonen, A;
Nielsen, T;
Hackshaw, A;
(2021)
Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation.
Advances in Therapy
10.1007/s12325-021-01738-2.
(In press).
|
|
|
Backen, AC;
Lopes, A;
Wasan, H;
Palmer, DH;
Duggan, M;
Cunningham, D;
Anthoney, A;
... Valle, JW; + view all
(2018)
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial.
British Journal of Cancer
, 119
pp. 27-35.
10.1038/s41416-018-0132-8.
|
|
|
Badia-Ramentol, J;
Gimeno-Valiente, F;
Duréndez, E;
Martínez-Ciarpaglini, C;
Linares, J;
Iglesias, M;
Cervantes, A;
... Tarazona, N; + view all
(2023)
The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practice.
Cancer Treatment Reviews
, 121
, Article 102643. 10.1016/j.ctrv.2023.102643.
|
 |
|
Baert, T;
Ferrero, A;
Sehouli, J;
O Donnell, DM;
González-Martín, A;
Joly, F;
Van der Velden, J;
... Ledermann, JA; + view all
(2021)
The systemic treatment of recurrent ovarian cancer revisited.
Annals of Oncology
, 32
(6)
pp. 710-725.
10.1016/j.annonc.2021.02.015.
|
|
Bahl, Amit;
Wilson, William;
Ball, Jessica;
Renninson, Emily;
Dubey, Sidharth;
Bravo, Alicia;
Foulstone, Emily;
... Churn, Mark; + view all
(2022)
Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer.
The Breast
, 66
pp. 69-76.
10.1016/j.breast.2022.09.005.
|
|
Balestrini, S;
Koepp, MJ;
Gandhi, S;
Rickman, HM;
Yen Shin, G;
Houlihan, CF;
Anders-Cannon, J;
... Sisodiya, SM; + view all
(2021)
Clinical outcomes of COVID-19 in long-term care facilities for people with epilepsy.
Epilepsy & Behavior
, 115
, Article 107602. 10.1016/j.yebeh.2020.107602.
|
|
Bangham, M;
Goldstein, R;
Walton, H;
Ledermann, JA;
(2016)
Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease.
Gynecologic Oncology Reports
, 18
pp. 22-24.
10.1016/j.gore.2016.10.004.
|
|
|
Barrington, SF;
Phillips, EH;
Counsell, N;
Hancock, B;
Pettengell, R;
Johnson, P;
Townsend, W;
... Radford, J; + view all
(2019)
Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study.
Journal of Clinical Oncology
, 37
(20)
pp. 1732-1741.
10.1200/JCO.18.01799.
|
|
|
Barrington, SF;
Phillips, EH;
Counsell, N;
Radford, J;
(2019)
Reply to H.J.A. Adams et al and C. Kobe et al.
Journal of Clinical Oncology
, 37
(34)
pp. 3325-3326.
10.1200/JCO.19.02056.
|
|
Barton, J;
Pacey, K;
Jain, N;
Kasia, T;
Edwards, D;
Thevanesan, C;
Straathof, K;
... Anderson, J; + view all
(2019)
Establishment and phenotyping of neurosphere cultures from primary neuroblastoma samples.
F1000Research
, 8
, Article 823. 10.12688/f1000research.18209.1.
|
|
|
Beaton, Laura;
Tregidgo, Henry Fj;
Znati, Sami A;
Forsyth, Sharon;
Counsell, Nicholas;
Clarkson, Matthew J;
Bandula, Steven;
... Sharma, Ricky A; + view all
(2022)
Phase 0 study of vandetanib-eluting radiopaque embolics as a pre-operative embolization treatment in patients with resectable liver malignancies.
Journal of Vascular and Interventional Radiology
, 33
(9)
1034-1044.e29.
10.1016/j.jvir.2022.04.033.
|
|
Beeken, RJ;
Croker, H;
Heinrich, M;
Smith, L;
Williams, K;
Hackshaw, A;
Hines, J;
... Fisher, A; + view all
(2016)
Study protocol for a randomised controlled trial of brief, habit-based, lifestyle advice for cancer survivors: exploring behavioural outcomes for the Advancing Survivorship Cancer Outcomes Trial (ASCOT).
BMJ Open
, 6
(11)
, Article e011646. 10.1136/bmjopen-2016-011646.
|
|
|
Bentham, R;
Litchfield, K;
Watkins, TBK;
Lim, EL;
Rosenthal, R;
Martinez-Ruiz, C;
Hiley, CT;
... McGranahan, N; + view all
(2021)
Using DNA sequencing data to quantify T cell fraction and therapy response.
Nature
, 597
pp. 555-560.
10.1038/s41586-021-03894-5.
|
|
Berek, JS;
Matulonis, UA;
Peen, U;
Ghatage, P;
Mahner, S;
Redondo, A;
Lesoin, A;
... Mirza, MR; + view all
(2018)
Safety and dose modification for patients receiving niraparib.
Annals of Oncology
, 29
(8)
pp. 1784-1792.
10.1093/annonc/mdy181.
|
|
Bhamani, A;
Katsampouris, E;
Bojang, F;
Verghese, P;
Creamer, A;
Prendecki, R;
Khaw, CR;
... Quaife, SL; + view all
(2025)
Uptake and 4-week outcomes of an ‘opt-out’ smoking cessation referral strategy in a London-based lung cancer screening setting.
BMJ Open Respiratory Research
, 12
(1)
, Article e002337. 10.1136/bmjresp-2024-002337.
|
|
Bhamani, Amyn;
Creamer, Andrew;
Verghese, Priyam;
Prendecki, Ruth;
Horst, Carolyn;
Tisi, Sophie;
Hall, Helen;
... SUMMIT consortium, .; + view all
(2025)
Low-dose CT for lung cancer screening in a high-risk population (SUMMIT): a prospective, longitudinal cohort study.
The Lancet Oncology
10.1016/S1470-2045(25)00082-8.
(In press).
|
|
Biasco, L;
Izotova, N;
Rivat, C;
Ghorashian, S;
Richardson, R;
Guvenel, A;
Hough, R;
... Amrolia, PJ; + view all
(2021)
Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients.
Nature Cancer
, 2
pp. 629-64.
10.1038/s43018-021-00207-7.
|
|
Bishton, MJ;
Rule, S;
Wilson, W;
Turner, D;
Patmore, R;
Clifton-Hadley, L;
McMillan, A;
... Haynes, A; + view all
(2020)
The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival.
British Journal of Haematology
, 190
(4)
pp. 545-554.
10.1111/bjh.16555.
|
|
Biswas, Dhruva;
Liu, Yun-Hsin;
Herrero, Javier;
Wu, Yin;
Moore, David A;
Karasaki, Takahiro;
Grigoriadis, Kristiana;
... Swanton, Charles; + view all
(2025)
Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma
adenocarcinoma.
Nature Cancer
, 6
pp. 86-101.
10.1038/s43018-024-00883-1.
|
|
Biswas, D;
Birkbak, NJ;
Rosenthal, R;
Hiley, CT;
Lim, EL;
Papp, K;
Boeing, S;
... TRACERx Consortium; + view all
(2019)
A clonal expression biomarker associates with lung cancer mortality.
Nature Medicine
, 25
pp. 1540-1548.
10.1038/s41591-019-0595-z.
|
|
Black, James RM;
Bartha, Gabor;
Abbott, Charles W;
Boyle, Sean M;
Karasaki, Takahiro;
Li, Bailiang;
Chen, Rui;
... Swanton, Charles; + view all
(2025)
Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma.
Nature Medicine
, 31
pp. 70-76.
10.1038/s41591-024-03216-y.
|
|
|
Black, James Robert Mackinlay;
(2023)
Genetic and non-genetic determinants of somatic evolution in cancer.
Doctoral thesis (Ph.D), UCL (University College London).
|
|
Blagden, SP;
Cook, AD;
Poole, C;
Howells, L;
McNeish, IA;
Dean, A;
Kim, J-W;
... Clamp, AR; + view all
(2020)
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial.
The Lancet Oncology
, 21
(7)
pp. 969-977.
10.1016/S1470-2045(20)30218-7.
|
|
|
Bookman, MA;
Okamoto, A;
Stuart, G;
Yanaihara, N;
Aoki, D;
Bacon, M;
Fujiwara, K;
... Ochiai, K; + view all
(2017)
Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.
Annals of Oncology
, 28
(S8)
viii30-viii35.
10.1093/annonc/mdx449.
|
|
Booth, S;
Plaschkes, H;
Kirkwood, AA;
Gibb, A;
Horgan, P;
Higham, C;
Oladipo, JM;
... Eyre, TA; + view all
(2020)
Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma.
Blood Advances
, 4
(18)
pp. 4337-4346.
10.1182/bloodadvances.2020002553.
|
|
|
Bosse, T;
Creutzberg, CL;
Crosbie, EJ;
Han, K;
Horeweg, N;
Leary, A;
Kroep, JR;
... RAINBO, Res Consortium; + view all
(2023)
Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program.
International Journal of Gynecological Cancer
, 33
(1)
pp. 109-117.
10.1136/ijgc-2022-004039.
|
|
Bray, T;
Sakai, N;
Dudek, A;
Fisher, C;
Rajesparan, K;
Lopes, A;
Ciurtin, C;
... Hall-Craggs, M; + view all
(2020)
Histographic Analysis of Oedema and Fat in Inflamed Bone Marrow based on Quantitative MRI.
European Radiology
, 313
10.1007/s00330-020-06785-x.
|
|
|
Bray, TJP;
Lopes, A;
Fisher, C;
Ciurtin, C;
Sen, D;
Hall-Craggs, MA;
(2019)
Sacroiliac Joint Ankylosis In Young Spondyloarthritis Patients Receiving Biologic Therapy: Observation of Serial MRI scans.
Arthritis and Rheumatology
, 71
(4)
pp. 594-598.
10.1002/art.40750.
|
|
Bray, TJP;
Singh, S;
Latifoltojar, A;
Rajesparan, K;
Rahman, F;
Narayanan, P;
Naaseri, S;
... Hall-Craggs, MA; + view all
(2017)
Diagnostic utility of whole body Dixon MRI in multiple myeloma: A multi-reader study.
PLoS One
, 12
(7)
, Article e0180562. 10.1371/journal.pone.0180562.
|
|
Brazil, L;
Swampillai, AL;
Mak, KM;
Edwards, D;
Mesiri, P;
Clifton-Hadley, L;
Shaffer, R;
... Short, SC; + view all
(2020)
Hydroxychloroquine and short-course radiotherapy in elderly patients with newly diagnosed high-grade glioma: a randomized phase II trial.
Neuro-Oncology Advances
, 2
(1)
10.1093/noajnl/vdaa046.
|
|
|
Bridgewater, J;
Lopes, A;
Beare, S;
Duggan, M;
Lee, D;
Ricamara, M;
McEntee, D;
... Valle, JW; + view all
(2016)
A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.
BMC Cancer
, 16
(1)
p. 153.
10.1186/s12885-016-2174-8.
|
|
|
Brown, N;
McBain, C;
Nash, S;
Hopkins, K;
Sanghera, P;
Saran, F;
Phillips, M;
... Mulholland, P; + view all
(2016)
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.
PLoS ONE
, 11
(5)
10.1371/journal.pone.0156369.
|
|
Brown, P;
Tan, A-C;
El-Esawi, MA;
Liehr, T;
Blanck, O;
Gladue, DP;
Almeida, GMF;
... Shalchyan, V; + view all
(2019)
Large expert-curated database for benchmarking document similarity detection in biomedical literature search.
Database
pp. 1-66.
10.1093/database/baz085.
|
|
Burnett, T;
Mozgunov, P;
Pallmann, P;
Villar, SS;
Wheeler, GM;
Jaki, T;
(2020)
Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs.
BMC Medicine
, 18
, Article 352. 10.1186/s12916-020-01808-2.
|
|
|
Burt, R;
Dey, A;
Aref, S;
Aguiar, M;
Akarca, A;
Bailey, K;
Day, W;
... Fielding, AK; + view all
(2019)
Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress.
Blood
, 134
(17)
pp. 1415-1429.
10.1182/blood.2019001398.
|
C
|
Cabeza-Segura, M;
Gambardella, V;
Gimeno-Valiente, F;
Carbonell-Asins, JA;
Alarcón-Molero, L;
González-Vilanova, A;
Zuñiga-Trejos, S;
... Fleitas, T; + view all
(2022)
Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma.
British Journal of Cancer
, 127
(12)
pp. 2198-2206.
10.1038/s41416-022-02005-z.
|
|
|
Cameron, AJM;
Veeriah, S;
Marshall, JJT;
Murray, ER;
Larijani, B;
Parker, PJ;
(2017)
Uncoupling TORC2 from AGC kinases inhibits tumour growth.
Oncotarget
, 8
(49)
pp. 84685-84696.
10.18632/oncotarget.20086.
|
|
|
Camilleri, M;
Sive, J;
Wilson, W;
Pang, G;
Jenner, R;
Phillips, E;
Popat, R;
... Yong, K; + view all
(2021)
COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial.
British Journal of Haematology
, 192
(1)
E14-E16.
10.1111/bjh.17168.
|
|
Camilleri, M;
Cuadrado, M;
Phillips, E;
Wilson, W;
Jenner, R;
Pang, G;
Kamora, S;
... Yong, K; + view all
(2021)
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
British Journal of Haematology
10.1111/bjh.17377.
(In press).
|
|
|
Castet, Florian;
Fabregat-Franco, Carles;
Bridgewater, John;
Kim, Jin Won;
Rimini, Margherita;
La Casta, Adelaida;
Lamarca, Angela;
... DURVABTC Group, Group; + view all
(2025)
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer.
Journal of Hepatology
10.1016/j.jhep.2025.05.020.
(In press).
|
|
Caswell, Deborah R;
Gui, Philippe;
Mayekar, Manasi K;
Law, Emily K;
Pich, Oriol;
Bailey, Chris;
Boumelha, Jesse;
... Swanton, Charles; + view all
(2023)
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.
Nature Genetics
10.1038/s41588-023-01592-8.
(In press).
|
|
Catto, JWF;
Khetrapal, P;
Ambler, G;
Sarpong, R;
Khan, MS;
Tan, M;
Feber, A;
... Kelly, JD; + view all
(2018)
Robot-assisted radical cystectomy with intracorporeal urinary diversion versus open radical cystectomy (iROC): protocol for a randomised controlled trial with internal feasibility study.
BMJ Open
, 8
(8)
, Article e020500. 10.1136/bmjopen-2017-020500.
|
|
|
Catto, JWF;
Khetrapal, P;
Ambler, G;
Sarpong, R;
Potyka, I;
Khan, S;
Tan, M;
... Kelly, JD; + view all
(2018)
Multidomain Quantitative Recovery Following Radical Cystectomy for Patients Within the Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion Versus Open Radical Cystectomy Randomised Controlled Trial: The First 30 Patients.
European Urology
, 74
(4)
pp. 531-534.
10.1016/j.eururo.2018.05.008.
|
|
Chafe, Shawn C;
Zhai, Kui;
Aghaei, Nikoo;
Miletic, Petar;
Huang, Zhi;
Brown, Kevin R;
Mobilio, Daniel;
... Singh, Sheila K; + view all
(2025)
A genome-wide in vivo CRISPR activation screen identifies BACE1 as a therapeutic vulnerability of lung cancer brain metastasis.
Science Translational Medicine
, 17
(805)
10.1126/scitranslmed.adu2459.
|
|
|
Chan, WY;
Counsell, N;
de Tute, R;
De-Silva, D;
Phillips, EH;
Cavenagh, J;
Adedayo, T;
... Yong, KL; + view all
(2022)
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial.
British Journal of Haematology
, 196
(4)
e33-e37.
10.1111/bjh.17903.
|
|
Chang, Ellen T;
Janes, Sam M;
Hackshaw, Allan;
Dur, Christina A Clarke;
Buist, Diana Sm;
Hubbell, Earl A;
(2023)
Overall and non-lung cancer incidence in the national lung screening trial (NLST) as indicators of potential for multi-cancer screening.
Presented at: 2023 ASCO Annual Meeting I.
|
|
Chapman, MA;
Sive, J;
Ambrose, J;
Roddie, C;
Counsell, N;
Lach, A;
Abbasian, M;
... Yong, K; + view all
(2018)
RNA-Seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.
Blood
, 132
(20)
pp. 2154-2165.
10.1182/blood-2018-05-849893.
|
|
Chavda, SJ;
Maciocia, PM;
Mesiri, P;
Counsell, N;
Kothari, J;
Bird, A;
Mariner, C;
... Yong, K; + view all
(2019)
A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1.
British Journal of Haematology
, 185
(2)
pp. 350-353.
10.1111/bjh.15487.
|
|
Chemi, F;
Rothwell, DG;
McGranahan, N;
Gulati, S;
Abbosh, C;
Pearce, SP;
Zhou, C;
... TRACERx Consortium, .; + view all
(2019)
Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse.
Nature Medicine
, 25
pp. 1534-1539.
10.1038/s41591-019-0593-1.
|
|
Cheok, Kathleen PL;
Kirkwood, Amy A;
Menne, Tobias;
Tholouli, Eleni;
Chaganti, Sridhar;
Mathew, Amrith;
Uttenthal, Ben;
... Roddie, Claire; + view all
(2022)
Severe presentations and high mortality from SARS-CoV-2 in patients undergoing chimeric antigen receptor (CAR-T) therapy: a UK NCCP analysis.
Leukemia & Lymphoma
, 63
(8)
pp. 1980-1984.
10.1080/10428194.2022.2057487.
|
|
Childs, A;
Kirkwood, A;
Edeline, J;
Tu, VL;
Watkins, J;
Lamarca, A;
Alrifai, D;
... Meyer, T; + view all
(2016)
Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours.
Endocrine-Related Cancer
, 23
(7)
pp. 563-570.
10.1530/ERC-16-0099.
|
|
|
Clamp, AR;
James, EC;
McNeish, IA;
Dean, A;
Kim, J-W;
O'Donnell, DM;
Hook, J;
... Ledermann, JA; + view all
(2019)
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
The Lancet
10.1016/s0140-6736(19)32259-7.
|
|
|
Clamp, AR;
Lorusso, D;
Oza, AM;
Aghajanian, C;
Oaknin, A;
Dean, A;
Colombo, N;
... Ledermann, JA; + view all
(2021)
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.
International Journal of Gynecological Cancer
10.1136/ijgc-2020-002240.
(In press).
|
|
Clark, JJ;
Dwyer, D;
Pinwill, N;
Clark, P;
Johnson, P;
Hackshaw, A;
(2021)
The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis.
The Lancet Oncology
, 22
(1)
pp. 66-73.
10.1016/S1470-2045(20)30619-7.
|
|
Cohen, OC;
Counsell, N;
Rabin, N;
Popat, R;
Owen, RG;
Popova, B;
Schofield, O;
... Yong, KL; + view all
(2019)
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
[Letter].
British Journal of Haematology
, 185
(5)
pp. 948-951.
10.1111/bjh.15649.
|
|
Coleman, RL;
Ledermann, JA;
(2019)
Maintenance treatment for recurrent ovarian carcinoma – Evidence supporting the efficacy and safety of PARP inhibitors.
[Review].
European Oncology and Haematology
, 15
(1)
pp. 29-40.
10.17925/EOH.2019.15.1.29.
|
|
Coleman, RL;
Oza, AM;
Lorusso, D;
Aghajanian, C;
Oaknin, A;
Dean, A;
Colombo, N;
... ARIEL3 investigators; + view all
(2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
The Lancet
, 390
(10106)
pp. 1949-1961.
10.1016/S0140-6736(17)32440-6.
|
|
Collinson, F;
Qian, W;
Fossati, R;
Lissoni, A;
Williams, C;
Parmar, M;
Ledermann, J;
... on behalf of the ICON1 collaborators; + view all
(2014)
Optimal treatment of early-stage ovarian cancer.
Ann Oncol
, 25
(6)
pp. 1165-1171.
10.1093/annonc/mdu116.
|
|
|
Colombo, N;
Ledermann, JA;
(2021)
Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines.
Annals of Oncology
, 32
(10)
pp. 1300-1303.
10.1016/j.annonc.2021.07.004.
|
|
Colombo, I;
Zaccarelli, E;
Del Grande, M;
Tomao, F;
Multinu, F;
Betella, I;
Ledermann, JA;
... Colombo, N; + view all
(2020)
ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies.
ESMO Open
, 5
, Article e000827. 10.1136/esmoopen-2020-000827.
|
|
|
Colombo, N;
Oza, AM;
Lorusso, D;
Aghajanian, C;
Oaknin, A;
Dean, A;
Weberpals, JI;
... Coleman, RL; + view all
(2020)
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
Gynecologic Oncology
10.1016/j.ygyno.2020.05.045.
(In press).
|
|
Colombo, N;
Sessa, C;
du Bois, A;
Ledermann, J;
McCluggage, WG;
McNeish, I;
Morice, P;
... Zeimet, AG; + view all
(2019)
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
International Journal of Gynecological Cancer
, 29
(4)
pp. 728-760.
10.1136/ijgc-2019-000308.
|
|
|
Colombo, N;
Sessa, C;
du Bois, A;
Ledermann, J;
McCluggage, WG;
McNeish, I;
Morice, P;
... ESMO–ESGO Ovarian Cancer Consensus Conference Working Group, .; + view all
(2019)
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
Annals of Oncology
, 30
(5)
pp. 672-705.
10.1093/annonc/mdz062.
|
|
Concin, N;
Creutzberg, CL;
Vergote, I;
Cibula, D;
Mirza, MR;
Marnitz, S;
Ledermann, JA;
... Matias-Guiu, X; + view all
(2021)
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.
Virchows Archiv
, 478
pp. 153-190.
10.1007/s00428-020-03007-z.
|
|
Concin, N;
Matias-Guiu, X;
Vergote, I;
Cibula, D;
Mirza, MR;
Marnitz, S;
Ledermann, J;
... Creutzberg, CL; + view all
(2021)
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
Radiotherapy and Oncology
, 154
pp. 327-353.
10.1016/j.radonc.2020.11.018.
|
|
Concin, N;
Matias-Guiu, X;
Vergote, I;
Cibula, D;
Mirza, MR;
Marnitz, S;
Ledermann, J;
... Creutzberg, CL; + view all
(2021)
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
International Journal Of Gynecological Cancer
, 31
(1)
pp. 12-39.
10.1136/ijgc-2020-002230.
|
|
|
Conibear, J;
Chia, B;
Ngai, Y;
Bates, AT;
Counsell, N;
Patel, R;
Eaton, D;
... Landau, D; + view all
(2018)
Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer.
BMJ Open
, 8
(4)
, Article e020690. 10.1136/bmjopen-2017-020690.
|
|
|
Coosemans, A;
Vankerckhoven, A;
Baert, T;
Boon, L;
Ruts, H;
Riva, M;
Blagden, S;
... Vergote, I; + view all
(2019)
Combining conventional therapy with immunotherapy: A risky business?
European Journal of Cancer
, 113
pp. 41-44.
10.1016/j.ejca.2019.02.014.
|
 |
|
Counsell, N;
Biri, D;
Fraczek, J;
Hackshaw, A;
(2017)
Publishing interim results of randomised clinical trials in peer-reviewed journals.
Clinical Trials
, 14
(1)
pp. 67-77.
10.1177/1740774516664689.
|
|
|
Cross, AJ;
Myles, J;
Greliak, P;
Hackshaw, A;
Halloran, S;
Benton, SC;
Addison, C;
... Raine, R; + view all
(2021)
Including a general practice endorsement letter with the testing kit in the Bowel Cancer Screening Programme: Results of a cluster randomised trial.
Journal of Medical Screening
10.1177/0969141321997480.
|
|
D
|
Das-Gupta, E;
Thomson, KJ;
Bloor, AJC;
Clark, AD;
Mackinnon, S;
Kayani, I;
Clifton-Hadley, L;
... Peggs, KS; + view all
(2019)
Allo-HSCT in transplant-naive patients with Hodgkin lymphoma: a single-arm, multicenter study.
Blood Advances
, 3
(24)
pp. 4264-4270.
10.1182/bloodadvances.2019001016.
|
|
de Boer, SM;
Powell, ME;
Mileshkin, L;
Katsaros, D;
Bessette, P;
Haie-Meder, C;
Ottevanger, PB;
... PORTEC study group, .; + view all
(2018)
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
The Lancet Oncology
, 19
(3)
pp. 295-309.
10.1016/S1470-2045(18)30079-2.
|
|
de Boer, SM;
Powell, ME;
Mileshkin, L;
Katsaros, D;
Bessette, P;
Haie-Meder, C;
Ottevanger, PB;
... Creutzberg, CL; + view all
(2016)
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.
Lancet Oncology
, 17
(8)
pp. 1114-1126.
10.1016/S1470-2045(16)30120-6.
|
|
|
de Boer, SM;
Powell, ME;
Mileshkin, L;
Katsaros, D;
Bessette, P;
Haie-Meder, C;
Ottevanger, PB;
... Tubiana-Mathieu, N; + view all
(2019)
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
The Lancet Oncology
10.1016/S1470-2045(19)30395-X.
(In press).
|
|
|
De Ruysscher, D;
Lueza, B;
Le Péchoux, C;
Johnson, DH;
O'Brien, M;
Murray, N;
Spiro, S;
... RTT-SCLC Collaborative Group; + view all
(2016)
Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis.
Annals of Oncology
, 27
(10)
pp. 1818-1828.
10.1093/annonc/mdw263.
|
|
|
de Tute, Ruth;
Counsell, Nicholas;
Clifton-Hadley, Laura;
D'Sa, Shirley;
Pratt, Guy;
Campbell, Gavin;
Campbell, Lauren;
... Auer, Rebecca; + view all
(2024)
Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemia.
Leukemia
, 38
pp. 822-828.
10.1038/s41375-024-02162-5.
|
|
Dehbi, H-M;
Hackshaw, A;
(2020)
Sample size calculation in randomised phase II selection trials using a margin of practical equivalence.
Trials
, 21
, Article 301. 10.1186/s13063-020-04248-8.
|
|
|
Dehbi, H-M;
Mallick, U;
Wadsley, J;
Newbold, K;
Harmer, C;
Hackshaw, A;
(2019)
Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
Lancet Diabetes and Endocrinology
, 7
(1)
pp. 44-51.
10.1016/S2213-8587(18)30306-1.
|
|
|
Dehbi, H-M;
Royston, P;
Hackshaw, A;
(2017)
Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards.
BMJ
(357)
, Article j2250. 10.1136/bmj.j2250.
|
|
|
Dettorre, GM;
Dolly, S;
Loizidou, A;
Chester, J;
Jackson, A;
Mukherjee, U;
Zambelli, A;
... OnCovid study group; + view all
(2021)
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score.
Journal for ImmunoTherapy of Cancer
, 9
(3)
, Article e002277. 10.1136/jitc-2020-002277.
|
|
|
Dietzen, Michelle;
Zhai, Haoran;
Lucas, Olivia;
Pich, Oriol;
Barrington, Christopher;
Lu, Wei-Ting;
Ward, Sophia;
... Kanu, Nnennaya; + view all
(2024)
Replication timing alterations are associated with mutation acquisition during breast and lung cancer evolution.
Nature Communications
, 15
(1)
, Article 6039. 10.1038/s41467-024-50107-4.
|
|
|
Dougherty, BA;
Lai, Z;
Hodgson, DR;
Orr, MCM;
Hawryluk, M;
Sun, J;
Yelensky, R;
... Barrett, JC; + view all
(2017)
Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
Oncotarget
, 8
(27)
pp. 43653-43661.
10.18632/oncotarget.17613.
|
E
|
Eaton, David J;
Brand, Douglas H;
Hava, Natasha;
Harrison, Mark;
Lopes, Andre;
Manoharan, Prakash;
Radhakrishna, Ganesh;
... Hawkins, Maria A; + view all
(2025)
Radiotherapy plan quality assurance in the ABC-07 trial of stereotactic body radiotherapy (SBRT) for locally advanced biliary tract cancer.
Clinical Oncology
, Article 103993. 10.1016/j.clon.2025.103993.
|
|
|
Elyashiv, O;
Ledermann, J;
Parmar, G;
Farrelly, L;
Counsell, N;
Feeney, A;
El-Khouly, F;
... Nicum, S; + view all
(2020)
ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy.
International Journal of Gynecologic Cancer
10.1136/ijgc-2020-002073.
(In press).
|
|
|
Elyashiv, O;
Wong, YNS;
Ledermann, JA;
(2021)
Frontline Maintenance Treatment for Ovarian Cancer.
Current Oncology Reports
, 23
(8)
, Article 97. 10.1007/s11912-021-01088-w.
|
|
|
Embleton, AC;
Clark, E;
Townsend, S;
Farrelly, L;
Jones, C;
Kaplan, R;
(2015)
Impact of retrospective data verification on the results of the academic-led ICON6 trial.
Presented at: 3rd International Clinical Trials Methodology Conference, Glasgow, UK.
|
|
|
Embleton-Thirsk, A;
Deane, E;
Townsend, S;
Farrelly, L;
Popoola, B;
Parker, J;
Rustin, G;
... Kaplan, R; + view all
(2019)
Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application.
Clinical Trials
, 16
(5)
pp. 502-511.
10.1177/1740774519862528.
|
|
|
Eminowicz, G;
Vaja, S;
Gallardo, D;
Kent, C;
Panades, M;
Mathew, T;
Anand, A;
... McCormack, M; + view all
(2025)
Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial.
European Journal of Cancer
, 220
, Article 115375. 10.1016/j.ejca.2025.115375.
|
|
Eminowicz, G;
Vaja, S;
Hackshaw, A;
McCormack, M;
(2025)
Response to letter Re: Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial.
European Journal of Cancer
, 222
, Article 115449. 10.1016/j.ejca.2025.115449.
|
|
Eminowicz, GKD;
(2016)
Standardisation and optimisation of radical radiotherapy for cervical cancer.
Doctoral thesis , UCL (University College London).
|
|
Enfield, Katey SS;
Colliver, Emma;
Lee, Claudia SY;
Magness, Alastair;
Moore, David A;
Sivakumar, Monica;
Grigoriadis, Kristiana;
... Angelova, Mihaela; + view all
(2024)
Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer.
Cancer Discovery
, 14
(1)
pp. 1-30.
10.1158/2159-8290.CD-23-1380.
|
|
Enshaei, A;
Joy, M;
Butler, E;
Kirkwood, AA;
Messina, M;
Pavoni, C;
Morgades, M;
... Moorman, AV; + view all
(2024)
A robust and validated integrated prognostic index for defining risk groups in adult acute lymphoblastic leukemia: an EWALL collaborative study.
Blood Advances
, 8
(5)
pp. 1155-1166.
10.1182/bloodadvances.2023011661.
|
|
Eschweiler, Simon;
Ramírez-Suástegui, Ciro;
Li, Yingcong;
King, Emma;
Chudley, Lindsey;
Thomas, Jaya;
Wood, Oliver;
... Ottensmeier, Christian H; + view all
(2022)
Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs.
Nature
10.1038/s41586-022-04685-2.
(In press).
|
|
Evens, Andrew M;
Rodday, Angie Mae;
Maurer, Matthew J;
Advani, Ranjana H;
Andre, Marc;
Gallamini, Andrea;
Hay, Annette E;
... Radford, John; + view all
(2023)
Development and Validation of the Early-Stage Hodgkin Lymphoma (HL) International Prognostication Index (E-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium.
In:
The 65th ASH Annual Meeting Abstracts.
(pp. p. 3058).
American Society of Hematology [Society Publisher]: San Diego, CA, USA.
|
|
Eyre, TA;
Wilson, W;
Kirkwood, AA;
Wolf, J;
Hildyard, C;
Plaschkes, H;
Griffith, J;
... Hatton, CSR; + view all
(2021)
Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP.
Blood Advances
, 5
(8)
pp. 2229-2236.
10.1182/bloodadvances.2021004286.
|
|
|
Eyre, TA;
Djebbari, F;
Kirkwood, AA;
Collins, GP;
(2020)
Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review.
Haematologica
, 105
(7)
pp. 1914-1924.
10.3324/haematol.2019.229948.
|
|
|
Eyre, TA;
Kirkwood, AA;
Gohill, S;
Follows, G;
Walewska, R;
Walter, H;
Cross, M;
... the UK CLL Forum; + view all
(2019)
Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.
British Journal of Haematology
, 185
(4)
pp. 656-669.
10.1111/bjh.15802.
|
|
Eyre, TA;
Kirkwood, AA;
Wolf, J;
Hildyard, C;
Mercer, C;
Plaschkes, H;
Griffith, J;
... Hatton, CSR; + view all
(2019)
Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.
British Journal of Haematology
, 187
(2)
pp. 185-194.
10.1111/bjh.16070.
|
|
F
|
Farah, N;
Kirkwood, AA;
Rahman, S;
Leon, T;
Jenkinson, S;
Gale, RE;
Patrick, K;
... Mansour, MR; + view all
(2018)
Prognostic impact of the absence of biallelic deletion at theTRGlocus for pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial.
Haematologica
, 103
(7)
e288-e292.
10.3324/haematol.2017.185801.
|
|
|
Fennell, D;
Danson, S;
Woll, P;
Forster, M;
Talbot, D;
Child, J;
Farrelly, L;
... Wheeler, G; + view all
(2020)
Ganetespib in combination with pemetrexed-platinum chemotherapy in patients with pleural Mesothelioma (MESO-02): A phase Ib trial.
Clinical Cancer Research
, 26
(18)
pp. 4748-4755.
10.1158/1078-0432.CCR-20-1306.
|
|
Fenwick, JD;
Landau, DB;
Baker, AT;
Bates, AT;
Eswar, C;
Garcia-Alonso, A;
Harden, SV;
... Counsell, N; + view all
(2020)
Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung Cancer.
International Journal of Radiation Oncology*Biology*Physics
, 106
(4)
pp. 733-742.
10.1016/j.ijrobp.2019.11.397.
|
|
|
Fiaccadori, Valeria;
Neven, Anouk;
Fortpied, Catherine;
Aurer, Igor;
Andre, Marc;
Federico, Massimo;
Counsell, Nicholas;
... Raemaekers, John MM; + view all
(2023)
Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy–a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials.
British Journal of Haematology
, 200
(6)
pp. 731-739.
10.1111/bjh.18594.
|
|
Forster, M;
Hackshaw, A;
De Pas, T;
Cobo, M;
Garrido, P;
Summers, Y;
Dingemans, AMC;
... Lee, SM; + view all
(2018)
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).
Lung Cancer
, 120
pp. 27-33.
10.1016/j.lungcan.2018.03.007.
|
|
|
Forster, M;
Mendes, R;
Harrington, K;
Guerrero-Urbano, T;
Baines, H;
Spanswick, V;
Ensell, L;
... Beare, S; + view all
(2016)
A phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck (HNSCC).
Presented at: 2016 ASCO Annual Meeting, Chicago, IL, USA.
|
|
Fotopoulou, C;
Hall, M;
Cruickshank, D;
Gabra, H;
Ganesan, R;
Hughes, C;
Kehoe, S;
... Sundar, S; + view all
(2017)
British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice.
European Journal of Obstetrics & Gynecology and Reproductive Biology
, 213
pp. 123-139.
10.1016/j.ejogrb.2017.04.016.
|
|
|
Fox, TA;
Kirkwood, AA;
Enfield, L;
O'Reilly, M;
Arulogun, S;
D'Sa, S;
O'Nions, J;
... Morris, EC; + view all
(2021)
Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies.
British Journal of Haematology
, 195
(5)
pp. 706-709.
10.1111/bjh.17836.
|
|
|
Fox, TA;
Troy-Barnes, E;
Kirkwood, AA;
Chan, WY;
Day, JW;
Chavda, SJ;
Kumar, EA;
... Ardeshna, KM; + view all
(2020)
Response to 'Impact of immunosuppression on mortality in critically ill COVID-19 patients'.
British Journal of Haematology
, 191
(3)
pp. 505-506.
10.1111/bjh.17110.
|
|
Fox, TA;
Troy-Barnes, E;
Kirkwood, AA;
Chan, WY;
Day, J;
Chavda, SJ;
Kumar, EA;
... Ardeshna, KM; + view all
(2020)
Clinical outcomes and risk factors for severe COVID‐19 infection in patients with haematological disorders receiving chemo‐ or immunotherapy.
British Journal of Haematology
, 191
(2)
pp. 194-206.
10.1111/bjh.17027.
|
|
Frankell, Alexander M;
Dietzen, Michelle;
Al Bakir, Maise;
Lim, Emilia L;
Karasaki, Takahiro;
Ward, Sophia;
Veeriah, Selvaraju;
... Swanton, Charles; + view all
(2024)
The evolution of lung cancer and impact of subclonal selection in TRACERx (vol 616, pg 525, 2023).
[Corrigendum].
Nature
, 631
, Article E15. 10.1038/s41586-024-07738-w.
|
|
|
Frankell, AM;
Dietzen, M;
Al Bakir, M;
Lim, EL;
Karasaki, T;
Ward, S;
Veeriah, S;
... Gilbert, K; + view all
(2023)
The evolution of lung cancer and impact of subclonal selection in TRACERx.
Nature
, 616
pp. 525-533.
10.1038/s41586-023-05783-5.
|
|
Fresneau, B;
Hackshaw, A;
Hawkins, DS;
Paulussen, M;
Anderson, JR;
Judson, I;
Litiere, S;
... Le Teuff, G; + view all
(2017)
Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study).
Pediatric Blood & Cancer
, 64
(8)
, Article e26457. 10.1002/pbc.26457.
|
|
|
Friedlander, M;
Matulonis, U;
Gourley, C;
du Bois, A;
Vergote, I;
Rustin, G;
Scott, C;
... Ledermann, J; + view all
(2018)
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
British Journal of Cancer
, 119
pp. 1075-1085.
10.1038/s41416-018-0271-y.
|
|
G
|
Gewandter, JS;
Dworkin, RH;
Turk, DC;
Devine, EG;
Hewitt, D;
Jensen, MP;
Katz, NP;
... Witter, J; + view all
(2020)
Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations.
The Journal of Pain
, 21
(9-10)
pp. 931-942.
10.1016/j.jpain.2019.12.003.
|
|
Ghimire, Bhagabati;
Landy, Rebecca;
Maroni, Roberta;
Smith, Samuel G;
Debiram-Beecham, Irene;
Sasieni, Peter D;
Fitzgerald, Rebecca C;
... Offman, Judith; + view all
(2023)
Predictors of the experience of a Cytosponge test: analysis of patient survey data from the BEST3 trial.
BMC Gastroenterology
, 23
(1)
, Article 7. 10.1186/s12876-022-02630-1.
|
|
|
Ghorani, E;
Reading, JL;
Henry, JY;
Massy, MRD;
Rosenthal, R;
Turati, V;
Joshi, K;
... Quezada, SA; + view all
(2020)
The T cell differentiation landscape is shaped by tumour mutations in lung cancer.
Nature Cancer
, 1
(5)
pp. 546-561.
10.1038/s43018-020-0066-y.
|
|
Ghorashian, Sara;
Lucchini, Giovanna;
Richardson, Rachel;
Nguyen, Kyvi;
Terris, Craig;
Guvenel, Aleks;
Oporto Espuelas, Macarena;
... Amrolia, Persis J; + view all
(2024)
CD19/CD22 targeting with co-transduced CAR T-cells to prevent antigen negative relapse after CAR T-cell therapy of B-ALL.
Blood
, 143
(2)
pp. 118-123.
10.1182/blood.2023020621.
|
|
Ghorashian, S;
Kramer, AM;
Onuoha, S;
Wright, G;
Bartram, J;
Richardson, R;
Albon, SJ;
... Amrolia, PJ; + view all
(2019)
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR.
Nature Medicine
, 25
pp. 1408-1414.
10.1038/s41591-019-0549-5.
|
|
Gimeno-Valiente, F;
Martin-Arana, J;
Tebar-Martinez, R;
Gambardella, V;
Martinez-Ciarpaglini, C;
Garcia-Mico, B;
Martinez-Castedo, B;
... Tarazona, N; + view all
(2023)
Sequencing paired tumor DNA and white blood cells improves circulating tumor DNA tracking and detects pathogenic germline variants in localized colon cancer.
ESMO Open
, 8
(6)
, Article 102051. 10.1016/j.esmoop.2023.102051.
|
|
|
Giurgiu, M;
Wittstruck, N;
Rodriguez-Fos, E;
González, RC;
Brückner, L;
Krienelke-Szymansky, A;
Helmsauer, K;
... Henssen, AG; + view all
(2024)
Decoil: Reconstructing Extrachromosomal DNA Structural Heterogeneity from Long-Read Sequencing Data.
In:
Research in Computational Molecular Biology. RECOMB 2024.
(pp. pp. 406-411).
Springer: Cham, Switzerland.
|
|
Giurgiu, Madalina;
Wittstruck, Nadine;
Rodriguez-Fos, Elias;
Chamorro Gonzalez, Rocio;
Brueckner, Lotte;
Krienelke-Szymansky, Annabell;
Helmsauer, Konstantin;
... Henssen, Anton G; + view all
(2024)
Reconstructing extrachromosomal DNA structural heterogeneity from long-read sequencing data using Decoil.
Genome Research
10.1101/gr.279123.124.
(In press).
|
|
|
Gleeson, M;
Counsell, N;
Cunningham, D;
Chadwick, N;
Lawrie, A;
Hawkes, EA;
McMillan, A;
... Linch, D; + view all
(2017)
Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial.
Annals of Oncology
, 28
(10)
pp. 2511-2516.
10.1093/annonc/mdx353.
|
|
|
Gleeson, M;
Counsell, N;
Cunningham, D;
Lawrie, A;
Clifton-Hadley, L;
Hawkes, E;
McMillan, A;
... Linch, D; + view all
(2021)
Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial.
British Journal of Haematology
, 192
(6)
pp. 1015-1019.
10.1111/bjh.16691.
|
|
Gleeson, M;
Hawkes, EA;
Cunningham, D;
Chadwick, N;
Counsell, N;
Lawrie, A;
Jack, A;
... Linch, D; + view all
(2016)
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial.
British Journal of Haematology
, 175
(4)
pp. 668-672.
10.1111/bjh.14287.
|
|
Glynne-Jones, R;
Adams, R;
Lopes, A;
Meadows, H;
(2017)
Clinical endpoints in trials of chemoradiation for patients with anal cancer.
[Review].
Lancet Oncology
, 18
(4)
E218-E227.
10.1016/S1470-2045(17)30190-0.
|
|
|
Glynne-Jones, R;
Hall, MR;
Lopes, A;
Pearce, S;
Goh, V;
Bosompem, S;
Bridgewater, J;
... Harrison, M; + view all
(2018)
BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC).
Heliyon
, 4
(9)
, Article e00804. 10.1016/j.heliyon.2018.e00804.
|
|
|
Glynne-Jones, R;
Meadows, HM;
Lopes, A;
Muirhead, R;
Sebag-Montefiore, D;
Adams, R;
ACTII study group;
(2020)
Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus. Results of a post-hoc analysis from the randomized phase III ACT II trial.
Annals of Oncology
, 31
(10)
pp. 1376-1385.
10.1016/j.annonc.2020.06.012.
|
|
Glynne-Jones, R;
Meadows, HM;
Lopes, A;
Riddle, P;
Duggan, M;
Sebag-Montefiore, D;
McDonald, A;
... Adams, R; + view all
(2020)
A Phase I/II Feasibility Study of Intravenous Cetuximab in Combination with 5 days Weekly Oral Capecitabine and Preoperative Radiotherapy in Rectal Cancer (XERXES).
Archives of Clinical and Biomedical Research
, 4
(4)
pp. 394-412.
10.26502/acbr.50170112.
|
|
|
Glynne-Jones, R;
Sebag-Montefiore, D;
Meadows, HM;
Cunningham, D;
Begum, R;
Adab, F;
Benstead, K;
... Kadalayil, L; + view all
(2017)
Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial.
LANCET ONCOLOGY
, 18
(3)
pp. 347-356.
10.1016/S1470-2045(17)30071-2.
|
|
|
Gohil, SH;
Maciocia, N;
Patrick, P;
Roberts, T;
Counsell, N;
Smith, P;
Clifton-Hadley, L;
... Nathwani, AC; + view all
(2018)
LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia.
Leukemia & Lymphoma
, 59
(7)
pp. 1730-1733.
10.1080/10428194.2017.1399311.
|
|
Gollins, S;
West, N;
Sebag-Montefiore, D;
Myint, AS;
Saunders, M;
Susnerwala, S;
Quirke, P;
... Beare, S; + view all
(2017)
Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations.
British Journal of Cancer
, 117
(9)
pp. 1286-1294.
10.1038/bjc.2017.294.
|
|
|
González Martín, A;
Oza, A;
Embleton, AC;
Pfisterer, J;
Ledermann, J;
Pujade-Lauraine, E;
Kristensen, G;
... Perren, T; + view all
(2019)
Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.
Gynecologic Oncology
, 152
(1)
10.1016/j.ygyno.2018.08.036.
|
|
|
Gore, M;
Hackshaw, A;
Brady, WE;
Penson, RT;
Zaino, R;
McCluggage, WG;
Ganesan, R;
... Gershenson, DM; + view all
(2019)
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
Gynecologic Oncology
, 153
(3)
pp. 541-548.
10.1016/j.ygyno.2019.03.256.
|
|
|
Gourley, C;
Miller, RE;
Hollis, RL;
Ledermann, JA;
(2020)
Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
Current Opinion in Oncology
, 32
(5)
pp. 442-450.
10.1097/CCO.0000000000000660.
|
|
Gourley, C;
Balmaña, J;
Ledermann, JA;
Serra, V;
Dent, R;
Loibl, S;
Pujade-Lauraine, E;
(2019)
Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
Journal of Clinical Oncology
, 37
(25)
pp. 2257-2269.
10.1200/JCO.18.02050.
|
|
Grayling, MJ;
Wheeler, GM;
(2020)
A review of available software for adaptive clinical trial design.
Clinical Trials
10.1177/1740774520906398.
(In press).
|
|
|
Green, HM;
Counsell, N;
Ward, A;
McCormack, M;
(2022)
Neoadjuvant Chemotherapy in Locally Advanced Cervical Carcinoma – a Role in Patients with Para-aortic Lymph Node Involvement? A 10-year Institutional Experience.
Clinical Oncology
, 34
(7)
e281-e290.
10.1016/j.clon.2021.12.005.
|
|
Greenwood, Hannah E;
Barber, Abigail R;
Edwards, Richard S;
Tyrrell, Will E;
George, Madeleine E;
Dos Santos, Sofia N;
Baark, Friedrich;
... Witney, Timothy H; + view all
(2024)
Imaging NRF2 activation in non-small cell lung cancer with positron emission tomography.
Nature Communications
, 15
, Article 10484. 10.1038/s41467-024-54852-4.
|
|
|
Grunewald, T;
Ledermann, JA;
(2016)
Targeted Therapies for Ovarian Cancer.
Best Practice & Research Clinical Obstetrics & Gynaecology
10.1016/j.bpobgyn.2016.12.001.
(In press).
|
H
|
Hackshaw, A;
(2023)
Modern cancer trials still lack information about QoL impacts on patients.
BMJ Oncology
, 2
(1)
, Article e000062. 10.1136/bmjonc-2023-000062.
|
|
|
Hackshaw, A;
Berg, CD;
(2021)
An efficient randomised trial design for multi-cancer screening blood tests: nested enhanced mortality outcomes of screening trial.
[Corrigendum].
The Lancet Oncology
, 22
(11)
E472.
|
|
Hackshaw, A;
Berg, CD;
(2021)
An efficient randomised trial design for multi-cancer screening blood tests: nested enhanced mortality outcomes of screening trial.
Lancet Oncology
, 22
(10)
pp. 1360-1362.
10.1016/S1470-2045(21)00204-7.
|
|
Hackshaw, A;
Cohen, SS;
Reichert, H;
Kansal, AR;
Chung, KC;
Ofman, JJ;
(2021)
Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK.
British Journal of Cancer
10.1038/s41416-021-01498-4.
(In press).
|
|
|
Hackshaw, Allan;
Clarke, Christina A;
Hartman, Anne-Renee;
(2022)
New genomic technologies for multi-cancer early detection: Rethinking the scope of cancer screening.
Cancer Cell
10.1016/j.ccell.2022.01.012.
(In press).
|
|
Hackshaw, Allan;
Fajardo, Otto;
Dafni, Urania;
Gelderblom, Hans;
Garrido, Pilar;
Siena, Salvatore;
Taylor, Matthew H;
... Nikolaidis, Christos; + view all
(2024)
Characteristics and Survival Outcomes of Patients With Metastatic RET Fusion-Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting.
JCO Precision Oncology
, 8
(8)
, Article e2300334. 10.1200/PO.23.00334.
|
|
Hackshaw, A;
Baum, M;
Fornander, T;
Nordenskjold, B;
Nicolucci, A;
Monson, K;
Forsyth, S;
... Sainsbury, R; + view all
(2009)
Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer.
J NATL CANCER I
, 101
(5)
341 - 349.
10.1093/jnci/djn498.
|
|
|
Hackshaw, AK;
Morris, JK;
Boniface, S;
Tang, JL;
Milenkovic, D;
(2018)
Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports.
BMJ
, 2018
(360)
, Article j3984. 10.1136/bmj.j5855.
|
|
|
Hainsworth, EG;
Shahmanesh, M;
Stevenson, F;
(2020)
Insights into the social context of living with a dual diagnosis of HIV and cancer: a qualitative, thematic analysis of popular discourse in London newspapers.
AIDS Care
, 32
(6)
pp. 793-799.
10.1080/09540121.2019.1653444.
|
|
Hainsworth, EG;
Shahmanesh, M;
Stevenson, F;
(2018)
Exploring the views and experiences of HIV positive patients treated for cancer: a systematic review of the literature.
AIDS Care
, 30
(5)
pp. 535-543.
10.1080/09540121.2017.1381332.
|
|
Hainsworth, Emma Georgina;
(2019)
HIV positive and treated for cancer: the social context and lived experiences of dual diagnosis and its treatment.
Doctoral thesis (Ph.D), UCL (University College London).
|
|
Halaska, MJ;
Haidopoulos, D;
Guyon, F;
Morice, P;
Zapardiel, I;
Kesic, V;
Cibula, D;
... Laky, R; + view all
(2017)
European Society of Gynecological Oncology Statement on Fibroid and Uterine Morcellation.
International Journal of Gynecological Cancer
, 27
(1)
pp. 189-192.
10.1097/IGC.0000000000000911.
|
|
Hall, MR;
Dehbi, H-M;
Banerjee, S;
Lord, R;
Clamp, A;
Ledermann, JA;
Nicum, S;
... Rustin, G; + view all
(2020)
A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.
Gynecologic Oncology
, 159
(3)
pp. 692-698.
10.1016/j.ygyno.2020.09.048.
|
|
Hall, M;
Gourley, C;
McNeish, I;
Ledermann, J;
Gore, M;
Jayson, G;
Perren, T;
... Kaye, S; + view all
(2013)
Targeted anti-vascular therapies for ovarian cancer: current evidence.
British Journal of Cancer
, 108
(2)
250 -258.
10.1038/bjc.2012.541.
|
|
|
Harter, P;
Pautier, P;
Van Nieuwenhuysen, E;
Reuss, A;
Redondo, A;
Lindemann, K;
Kurzeder, C;
... Marme, F; + view all
(2020)
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34).
International Journal of Gynecologic Cancer
10.1136/ijgc-2020-001572.
(In press).
|
|
|
Hawkins, Maria;
Collins Fekete, Charles-Antoine;
Royle, Gary;
Zhang, Ying;
Lopes, Andre;
Begum, Rubina;
West, Nick P;
... Shen, Zhuoyan; + view all
(2025)
Tumour Cell Density Quantified by Artificial Intelligence Enables Precise Chemo-Radiotherapy Planning for Locally Advanced Rectal Cancer Patients: A Post-hoc Study of the Phase 3 ARISTOTLE Trial.
The Lancet Oncology
(In press).
|
|
Heinrich, M;
Fisher, A;
Paton, B;
McCourt, O;
Beeken, RJ;
Hackshaw, A;
Wardle, J;
(2016)
Lifestyle in Multiple Myeloma - a longitudinal cohort study protocol.
BMC Cancer
, 16
, Article 387. 10.1186/s12885-016-2407-x.
|
|
|
Hill, Mark Stephen;
(2017)
The genetic basis of sexual antagonism in Drosophila melanogaster.
Doctoral thesis , UCL (University College London).
|
|
Hirst, Y;
Kerrison, R;
Kobayashi, LC;
Counsell, N;
Djedovic, N;
Ruwende, J;
Stewart, M;
(2016)
Text Reminders in Colorectal Cancer Screening (TRICCS): Protocol for a randomised controlled trial.
BMC Public Health
10.1186/s12889-016-2733-6.
|
|
|
Hirst, Y;
Skrobanski, H;
Kerrison, RS;
Kobayashi, LC;
Counsell, N;
Djedovic, N;
Ruwende, J;
... von Wagner, C; + view all
(2017)
Text-message Reminders in Colorectal Cancer Screening (TRICCS): a randomised controlled trial.
British Journal of Cancer
, 116
pp. 1408-1414.
10.1038/bjc.2017.117.
|
|
Hobor, S;
Al Bakir, M;
Hiley, CT;
Skrzypski, M;
Frankell, AM;
Bakker, B;
Watkins, TBK;
... Clipson, A; + view all
(2024)
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling.
Nature Communications
, 15
, Article 4871. 10.1038/s41467-024-47606-9.
|
|
Hodgson, DR;
Dougherty, BA;
Lai, Z;
Fielding, A;
Grinsted, L;
Spencer, S;
O'Connor, MJ;
... Barrett, JC; + view all
(2018)
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
British Journal of Cancer
, 119
pp. 1401-1409.
10.1038/s41416-018-0274-8.
|
|
Horgan, D;
Borisch, B;
Cattaneo, I;
Caulfield, M;
Chiti, A;
Chomienne, C;
Cole, A;
... von Meyenn, M; + view all
(2022)
Factors Affecting Citizen Trust and Public Engagement Relating to the Generation and Use of Real-World Evidence in Healthcare.
International Journal of Environmental Research and Public Health
, 19
(3)
, Article 1674. 10.3390/ijerph19031674.
|
|
|
Horgan, Denis;
Capoluongo, Ettore;
Dube, France;
Trapani, Dario;
Malapelle, Umberto;
Rovite, Vita;
Omar, Muhammad Imran;
... Subbiah, Vivek; + view all
(2023)
Clouds across the new dawn for clinical, diagnostic and biological data: accelerating the development, delivery and uptake of personalized medicine.
Diagnosis
, 10
(4)
pp. 356-362.
10.1515/dx-2023-0022.
|
|
Hoskin, Peter;
Sundar, Santhanam;
Reczko, Krystyna;
Forsyth, Sharon;
Mithal, Natasha;
Sizer, Bruce;
Bloomfield, David;
... Hackshaw, Allan; + view all
(2015)
A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer.
JNCI: Journal of the National Cancer Institute
, 107
(10)
, Article djv197. 10.1093/jnci/djv197.
|
|
Hoskin, Peter J;
Hopkins, Kirsten;
Misra, Vivek;
Holt, Tanya;
McMenemin, Rhona;
McKinna, Fiona;
Madhavan, Krishnaswamy;
... Lopes, Andre; + view all
(2022)
Prognostic factors for survival and ambulatory status at 8 weeks with metastatic spinal cord compression in the SCORAD randomised trial.
Radiotherapy and Oncology
, 173
pp. 77-83.
10.1016/j.radonc.2022.05.017.
|
|
Hoskin, Peter J;
Reczko, Krystyna;
Rashid, Memuna;
Hackshaw, Allan;
Lopes, Andres;
SCORAD Investigators;
(2024)
Quality-of-life outcomes in metastatic spinal cord compression: findings from the SCORAD trial.
JNCI: Journal of the National Cancer Institute
, 116
(7)
pp. 1087-1094.
10.1093/jnci/djae039.
|
|
Hoskin, PJ;
Malhi, Aman;
Reczko, Krystyna;
Hackshaw, Allan;
(2024)
Urinary biomarkers in metastatic bone pain: Results from a multicentre randomized trial of ibandronate compared to single dose radiotherapy for localized metastatic bone pain in prostate cancer (RIB).
Journal of Bone Oncology
, 47
, Article 100624. 10.1016/j.jbo.2024.100624.
|
|
|
Hoskin, P;
Popova, B;
Schofield, O;
Brammer, C;
Robinson, M;
Brunt, AM;
Madhavan, K;
... Kirkwood, AA; + view all
(2021)
4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial.
The Lancet Oncology
, 22
(3)
pp. 332-340.
10.1016/S1470-2045(20)30686-0.
|
|
Hoskin, PJ;
Hopkins, K;
Misra, V;
Holt, T;
McMenemin, R;
Dubois, D;
McKinna, F;
... Lopes, A; + view all
(2019)
Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial.
JAMA
, 322
(21)
pp. 2084-2094.
10.1001/jama.2019.17913.
|
|
Hough, R;
Lopes, A;
Patrick, P;
Russell, N;
Raj, K;
Tholouli, E;
Snowden, JA;
... Marks, D; + view all
(2022)
Primary graft failure, but not relapse, may be identified by early chimerism following double cord blood unit transplantation.
Blood Advances
, 6
(7)
pp. 2414-2426.
10.1182/bloodadvances.2021005106.
|
|
Hughes, J;
Gyertson, K;
Carballo, L;
Plant, H;
Sharman, M;
Ruane, K;
Mendoza-Naranjo, A;
... Fisher, P; + view all
(2021)
A feasibility trial of acupuncture in cancer patients undergoing radiotherapy treatment.
Complementary Therapies in Clinical Practice
, 43
, Article 101372. 10.1016/j.ctcp.2021.101372.
|
|
Hutchison, Iain L;
Ridout, Fran;
Cheung, Sharon MY;
Shah, Neil;
Hardee, Peter;
Surwald, Christian;
Thiruchelvam, Janavikulam;
... Hackshaw, Allan; + view all
(2022)
Correction to: Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort.
British Journal of Cancer
, 126
(5)
, Article 831. 10.1038/s41416-021-01678-2.
|
|
|
Hutchison, I;
Hackshaw, A;
(2020)
Reply to Comment(s) on "Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort".
British Journal of Cancer
, 123
pp. 1200-1201.
10.1038/s41416-020-0983-7.
|
|
Hutchison, IL;
Ridout, F;
Cheung, SMY;
Shah, N;
Hardee, P;
Surwald, C;
Thiruchelvam, J;
... Hackshaw, A; + view all
(2019)
Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort.
British Journal of Cancer
10.1038/s41416-019-0587-2.
(In press).
|
|
|
Hynds, Robert E;
Huebner, Ariana;
Pearce, David R;
Hil, Mark S;
Akarca, Ayse U;
Moore, David A;
Ward, Sophia;
... Swanton, Charles; + view all
(2024)
Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models.
Nature Communications
, 15
, Article 4653. 10.1038/s41467-024-47547-3.
|
|
|
Hynds, RE;
Ben Aissa, A;
Gowers, KHC;
Watkins, TBK;
Bosshard-Carter, L;
Rowan, AJ;
Veeriah, S;
... Janes, SM; + view all
(2018)
Expansion of airway basal epithelial cells from primary human non-small cell lung cancer tumors.
International Journal of Cancer
, 143
(1)
pp. 160-166.
10.1002/ijc.31383.
|
|
I
|
Illidge, TM;
Phillips, EH;
Counsell, N;
Pettengell, R;
Johnson, PWM;
Culligan, DJ;
Popova, B;
... Radford, J; + view all
(2020)
Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma.
Blood Advances
, 4
(1)
pp. 203-206.
10.1182/bloodadvances.2019001023.
|
|
J
|
Jamal-Hanjani, M;
Wilson, GA;
McGranahan, N;
Birkbak, NJ;
Watkins, TBK;
Veeriah, S;
Shafi, S;
... Swanton, C; + view all
(2017)
Tracking the Evolution of Non-Small-Cell Lung Cancer.
New England Journal of Medicine
, 376
(22)
pp. 2109-2121.
10.1056/NEJMoa1616288.
|
|
Jang, JYA;
Yanaihara, N;
Pujade-Lauraine, E;
Mikami, Y;
Oda, K;
Bookman, M;
Ledermann, J;
... Okamoto, A; + view all
(2017)
Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference.
Journal of Gynecologic Oncology
, 28
(4)
, Article e54. 10.3802/jgo.2017.28.e54.
|
|
Javaid, F;
Pilotti, C;
Camilli, C;
Kallenberg, D;
Bahou, C;
Blackburn, J;
R. Baker, J;
... Chudasama, V; + view all
(2021)
Leucine-rich alpha-2-glycoprotein 1 (LRG1) as a novel ADC target.
RSC Chemical Biology
, 2
(4)
pp. 1206-1220.
10.1039/d1cb00104c.
|
|
|
Jenkinson, S;
Kirkwood, AA;
Goulden, N;
Vora, A;
Linch, DC;
Gale, RE;
(2015)
Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial.
Leukemia
10.1038/leu.2015.206.
(In press).
|
|
|
Jitlal, M;
Khan, I;
Lee, SM;
Hackshaw, A;
(2012)
Stopping clinical trials early for futility: retrospective analysis of several randomised clinical studies.
British Journal of Cancer
, 107
(6)
910 - 917.
10.1038/bjc.2012.344.
|
|
|
Johnson, P;
Federico, M;
Kirkwood, A;
Fossa, A;
Berkahn, L;
Carella, A;
d'Amore, F;
... Barrington, S; + view all
(2016)
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.
New England Journal of Medicine
, 374
(25)
pp. 2419-2429.
10.1056/NEJMoa1510093.
|
|
|
Joshi, K;
Robert de Massy, M;
Ismail, M;
Reading, JL;
Uddin, I;
Woolston, A;
Hatipoglu, E;
... Chain, B; + view all
(2019)
Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer.
Nature Medicine
, 25
pp. 1549-1559.
10.1038/s41591-019-0592-2.
|
K
|
Kadalayil, L;
Benini, R;
Pallan, L;
O'Beirne, J;
Marelli, L;
Yu, D;
Hackshaw, A;
... Meyer, T; + view all
(2013)
A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer.
Ann Oncol
, 24
(10)
pp. 2565-2570.
10.1093/annonc/mdt247.
|
|
|
Kanu, Nnennaya;
Lu, Wei-Ting;
Swanton, Charles;
Bartek, Jiri;
(2025)
TRACERx analysis identifies a role for FAT1 in regulating chromosomal instability and whole-genome doubling via Hippo signalling.
Nature Cell Biology
, 27
(1)
pp. 154-168.
10.1038/s41556-024-01558-w.
|
|
|
Karam, A;
Ledermann, JA;
Kim, J-W;
Sehouli, J;
Lu, K;
Gourley, C;
Katsumata, N;
... Ochiai, K; + view all
(2017)
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.
Annals of Oncology
, 28
(4)
pp. 711-717.
10.1093/annonc/mdx011.
|
|
Kerrison, R;
McGregor, LM;
Marshall, S;
Isitt, J;
Counsell, N;
Wardle, J;
Von Wagner, C;
(2016)
Use of a twelve month's self referral reminder to faciliate uptake of bowel scope (flexible sigmoidoscopy screening) in previous non-responders: a London-based feasibility study.
British Journal of Cancer
, 114
pp. 751-758.
10.1038/bjc.2016.43.
|
|
|
Kerrison, R;
McGregor, LM;
Von Wagner, C;
Counsell, N;
(2018)
Use of two self-referral reminders and a theory-based leaflet to increase the uptake of flexible sigmoidoscopy in the English Bowel Scope Screening Programme: results from a randomised controlled trial in London.
Annals of Behavioral Medicine
, 52
(11)
pp. 941-951.
10.1093/abm/kax068.
|
|
|
Kerrison, RS;
McGregor, LM;
Marshall, S;
Isitt, J;
Counsell, N;
Rees, CJ;
von Wagner, C;
(2017)
Improving uptake of flexible sigmoidoscopy screening: a randomized trial of nonparticipant reminders in the English Screening Programme.
Endoscopy
, 49
(1)
pp. 35-43.
10.1055/s-0042-118452.
|
|
|
Kerrison, RS;
McGregor, LM;
Marshall, S;
Isitt, J;
Counsell, N;
Wardle, J;
von Wagner, C;
(2016)
Use of a 12 months' self-referral reminder to facilitate uptake of bowel scope (flexible sigmoidoscopy) screening in previous non-responders: a London-based feasibility study.
British Journal of Cancer
, 114
(7)
pp. 751-758.
10.1038/bjc.2016.43.
|
|
|
Khan, I;
Morris, S;
Hackshaw, A;
Lee, SM;
(2015)
Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy.
BMJ Open
, 5
(7)
, Article e006733. 10.1136/bmjopen-2014-006733.
|
|
|
Khan, I;
Sarker, SJ;
Hackshaw, AK;
(2012)
Smaller sample sizes for phase II trials based on exact tests with actual error rates by trading-off their nominal levels of significance and power.
British Journal of Cancer
, 107
1801 -1809.
10.1038/bjc.2012.444.
|
|
|
Khoja, L;
Nolan, K;
Mekki, R;
Milani, A;
Mescallado, N;
Ashcroft, L;
Hasan, J;
... Jayson, GC; + view all
(2016)
Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK.
Clinical Oncology
, 28
(12)
pp. 760-765.
10.1016/j.clon.2016.06.011.
|
|
|
King, J;
Palmer, DH;
Johnson, P;
Ross, P;
Hubner, RA;
Sumpter, K;
Darby, S;
... Meyer, T; + view all
(2017)
Sorafenib for the Treatment of Advanced Hepatocellular Cancer – a UK Audit.
Clinical Oncology
, 29
(4)
pp. 256-262.
10.1016/j.clon.2016.11.012.
|
|
Kirk, R.J.;
(2005)
Structural and functional analysis of the proteasome inhibitor PL31 and its interaction with the F-box protein Fbxo7.
Doctoral thesis , University of London.
|
|
|
Kirkwood, AA;
Cox, T;
Hackshaw, A;
(2013)
Application of methods for central statistical monitoring in clinical trials.
Clinical Trials
, 10
(5)
783 - 806.
10.1177/1740774513494504.
|
|
|
Klein, Eric A;
Madhavan, Sarina;
Beer, Tomasz M;
Bettegowda, Chetan;
Liu, Minetta C;
Hartman, Anne-Renee;
Hackshaw, Allan;
(2023)
Dying To Find Out: The Cost of Time at the Dawn of the Multicancer Early Detection Era.
Cancer Epidemiology, Biomarkers & Prevention
10.1158/1055-9965.EPI-22-1275.
(In press).
|
|
|
Koh, Kexin;
Scott, Rachel;
Cespedes Feliciano, Elizabeth M;
Janowitz, Tobias;
Goncalves, Marcus D;
White, Eileen P;
Laird, Barry JA;
... Jamal-Hanjani, Mariam; + view all
(2025)
Cancer-Associated Cachexia: Bridging Clinical Findings with Mechanistic Insights in Human Studies.
Cancer Discovery
OF1-OF26.
10.1158/2159-8290.CD-25-0293.
|
|
Koutoukidis, DA;
Land, J;
Hackshaw, A;
Heinrich, M;
McCourt, O;
Beeken, RJ;
Philpott, S;
... Yong, KL; + view all
(2020)
Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design.
British Journal of Cancer
10.1038/s41416-020-0866-y.
(In press).
|
|
|
Koutoukidis, DA;
Land, J;
Hackshaw, A;
Heinrich, M;
McCourt, O;
Beeken, RJ;
Philpott, S;
... Yong, KL; + view all
(2020)
Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design.
British Journal of Cancer
10.1038/s41416-020-0866-y.
(In press).
|
|
|
Kristeleit, RS;
Oaknin, A;
Ray-Coquard, I;
Leary, A;
Balmaña, J;
Drew, Y;
Oza, AM;
... McNeish, IA; + view all
(2019)
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety.
International Journal of Gynecological Cancer
, 29
(9)
pp. 1396-1404.
10.1136/ijgc-2019-000623.
|
|
|
Kuhnl, A;
Kirkwood, AA;
Roddie, C;
Menne, T;
Tholouli, E;
Bloor, A;
Besley, C;
... Townsend, W; + view all
(2023)
CAR T in patients with large B-cell lymphoma not fit for autologous transplant.
British Journal of Haematology
, 202
(1)
pp. 65-73.
10.1111/bjh.18810.
|
|
Kuhnl, A;
Roddie, C;
Kirkwood, AA;
Chaganti, S;
Norman, J;
Lugthart, S;
Osborne, W;
... Mikhaeel, NG; + view all
(2024)
Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK.
British Journal of Haematology
, 205
(2)
pp. 483-494.
10.1111/bjh.19453.
|
|
Kuhnl, Andrea;
Roddie, Claire;
Kirkwood, Amy A;
Tholouli, Eleni;
Menne, Tobias;
Patel, Amit;
Besley, Caroline;
... McMillan, Andrew; + view all
(2022)
A national service for delivering CD19 CAR-Tin large B-cell lymphoma – The UK real-world experience.
British Journal of Haematology
, 198
(3)
pp. 492-502.
10.1111/bjh.18209.
|
|
Kühnl, A;
Cunningham, D;
Counsell, N;
Hawkes, EA;
Qian, W;
Smith, P;
Chadwick, N;
... Linch, D; + view all
(2017)
Outcome of Elderly Patients with Diffuse Large B-cell Lymphoma Treated with R-CHOP: Results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.
Annals of Oncology
, 28
(7)
pp. 1540-1546.
10.1093/annonc/mdx128.
|
|
Kularatne, B;
Arora, R;
Elshstein, G;
Guppy, N;
Kirkwood, A;
Meyer, T;
Kristeleit, RS;
(2016)
Immunohistochemistry (IHC) evaluation of a novel 4-protein prognostic and predictive biomarker panel in endometrial cancer (EC).
In:
Abstract Book of the 41st ESMO Congress (ESMO 2016), 7-11 October 2016, Copenhagen, Denmar.
Oxford University Press (OUP): Policy A1
|
|
Kularatne, BY;
(2017)
The identification of novel biomarkers to guide treatment in endometrial cancer.
Doctoral thesis , UCL (University College London).
|
|
Kurtz, JE;
Gebski, V;
Sukhin, V;
Carey, M;
Kong, I;
Glasspool, RM;
Berek, JS;
... Friedlander, M; + view all
(2021)
Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
Gynecologic Oncology
, 161
(2)
pp. 502-507.
10.1016/j.ygyno.2021.02.018.
|
|
Kwan, TT;
Oza, AM;
Tinker, A;
Ray-Coquard, I;
Oaknin, A;
Aghajanian, C;
Lorusso, D;
... Swisher, EM; + view all
(2021)
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib.
JAMA Oncology
10.1001/jamaoncol.2021.4664.
|
L
|
Lacas, B;
Carmel, A;
Landais, C;
Wong, SJ;
Licitra, L;
Tobias, JS;
Burtness, B;
... MACH-NC Collaborative Group; + view all
(2021)
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.
Radiotherapy and Oncology
, 156
pp. 281-293.
10.1016/j.radonc.2021.01.013.
|
|
Lally, P;
Miller, N;
Roberts, A;
Beeken, RJ;
Greenfield, DM;
Potts, HWW;
Counsell, N;
... Fisher, A; + view all
(2022)
An app with brief behavioural support to promote physical activity after a cancer diagnosis (APPROACH): study protocol for a pilot randomised controlled trial.
Pilot and Feasibility Studies
, 8
(1)
, Article 74. 10.1186/s40814-022-01028-w.
|
|
|
Lally, Phillippa;
Kennedy, Fiona;
Smith, Susan;
Beeken, Rebecca J;
Buck, Caroline;
Thomas, Chloe;
Counsell, Nicholas;
... Fisher, Abi; + view all
(2024)
The feasibility and acceptability of an app-based intervention with brief behavioural support (APPROACH) to promote brisk walking in people diagnosed with breast, prostate and colorectal cancer in the UK.
Cancer Medicine
, 13
(6)
, Article e7124. 10.1002/cam4.7124.
|
|
Lamarca, A;
Ross, P;
Wasan, HS;
Hubner, RA;
McNamara, MG;
Lopes, A;
Manoharan, P;
... Valle, JW; + view all
Advanced intrahepatic cholangiocarcinoma: post-hoc analysis of the ABC-01, -02 and -03 clinical trials.
Journal of the National Cancer Institute
10.1093/jnci/djz071.
(In press).
|
|
|
Lanceley, A;
Berzuini, C;
Burnell, M;
Gessler, S;
Morris, S;
Ryan, A;
Ledermann, JA;
(2017)
Ovarian Cancer Follow-up: A Preliminary Comparison of 2 Approaches.
International Journal of Gynecological Cancer
, 27
(1)
pp. 59-68.
10.1097/IGC.0000000000000877.
|
|
Land, J;
McCourt, O;
Heinrich, M;
Beeken, RJ;
Koutoukidis, DA;
Paton, B;
Yong, K;
... Fisher, A; + view all
(2020)
The adapted Zelen was a feasible design to trial exercise in myeloma survivors.
Journal of Clinical Epidemiology
, 125
pp. 76-83.
10.1016/j.jclinepi.2020.04.004.
|
|
|
Landau, DB;
Hughes, L;
Baker, A;
Bates, AT;
Bayne, MC;
Counsell, N;
Garcia-Alonso, A;
... Fenwick, JD; + view all
(2016)
IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer.
International Journal of Radiation Oncology - Biology - Physics
, 95
(5)
pp. 1367-1377.
10.1016/j.ijrobp.2016.03.031.
|
|
|
Langley, RE;
Duong, T;
Clarke, NW;
Kynaston, K;
Rosen, SD;
Nankivell, M;
Dearnaley, D;
... Abel, P; + view all
(2018)
PATCH - Prostate adenocarcinoma: transcutaneous hormones. A randomised comparison evaluating cardiovascular morbidity and mortality of transdermal oestradiol versus luteinising hormone-releasing hormone agonists in advanced prostate cancer.
Presented at: The British Associations of Urological Surgeons (BAUS) Annual Scientific Meeting, Liverpool, UK.
|
|
|
Laszlo, HE;
Seward, E;
Ayling, RM;
Lake, J;
Malhi, A;
Stephens, C;
Pritchard-Jones, K;
... Machesney, M; + view all
(2021)
Faecal immunochemical test for patients with 'high-risk' bowel symptoms: a large prospective cohort study and updated literature review.
British Journal of Cancer
10.1038/s41416-021-01653-x.
(In press).
|
|
|
Laszlo, HE;
Seward, E;
Ayling, R;
Lake, J;
Malhi, A;
Hackshaw, A;
Stephens, C;
... Machesney, M; + view all
(2020)
Quantitative faecal immunochemical test for patients with 'high risk' bowel symptoms: a prospective cohort study.
MedRxiv: Cold Spring Harbor, NY, USA.
|
|
Latifoltojar, A;
Punwani, S;
Lopes, A;
Humphries, PD;
Klusmann, M;
Menezes, LJ;
Daw, S;
... Taylor, SA; + view all
(2019)
Whole-body MRI for staging and interim response monitoring
in paediatric and adolescent Hodgkin's lymphoma: a comparison
with multi-modality reference standard including 18F-FDG-PET-CT.
European Radiology
, 29
(1)
pp. 202-212.
10.1007/s00330-018-5445-8.
|
|
|
Le Tourneau, Christophe;
Perret, Camille;
Hackshaw, Allan;
Blay, Jean-Yves;
Nabholz, Christoph;
Geissler, Jan;
Do, Thy;
... Dienstmann, Rodrigo; + view all
(2022)
An Approach to Solving the Complex Clinicogenomic Data Landscape in Precision Oncology: Learnings From the Design of WAYFIND-R, a Global Precision Oncology Registry.
JCO Precision Oncology
, 6
(6)
, Article e2200019. 10.1200/PO.22.00019.
|
|
Leary, A;
Tan, D;
Ledermann, J;
(2021)
Immune checkpoint inhibitors in ovarian cancer: where do we stand?
Therapeutic Advances in Medical Oncology
, 13
10.1177/17588359211039899.
|
|
|
Lechner, M;
Liu, J;
Counsell, N;
Gillespie, D;
Chandrasekharan, D;
Ta, NH;
Jumani, K;
... Lund, VJ; + view all
(2022)
The COVANOS trial – insight into post-COVID olfactory dysfunction and the role of smell training.
Rhinology
, 60
(3)
pp. 188-199.
10.4193/Rhin21.470.
|
|
Lechner, M;
Liu, J;
Counsell, N;
Gillespie, D;
Chandrasekharan, D;
Ta, NH;
Jumani, K;
... Lund, VJ; + view all
(2022)
The burden of olfactory dysfunction during the COVID-19 pandemic in the United Kingdom.
Rhinology
10.4193/Rhin22.232.
|
|
Lechner, M;
Liu, J;
Counsell, N;
Ta, NH;
Rocke, J;
Anmolsingh, R;
Eynon-Lewis, N;
... Philpott, C; + view all
(2021)
Course of symptoms for loss of sense of smell and taste over time in one thousand forty-one healthcare workers during the Covid-19 pandemic: Our experience.
Clinical Otolaryngology
, 46
(2)
pp. 451-457.
10.1111/coa.13683.
|
|
Lechner, M;
Takahashi, Y;
Turri-Zanoni, M;
Liu, J;
Counsell, N;
Hermsen, M;
Kaur, RP;
... Hanna, EY; + view all
(2022)
Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma.
European Journal of Cancer
, 162
pp. 221-236.
10.1016/j.ejca.2021.09.046.
|
|
Lechner, Matt;
Liu, Jacklyn;
Counsell, Nicholas;
Yan, Carol H;
Paun, Santdeep;
Eynon-Lewis, Nicholas;
Sutton, Liam;
... Patel, Zara M; + view all
(2023)
High prevalence of persistent smell loss and qualitative smell dysfunction during the coronavirus disease 2019 (COVID-19) pandemic in the United States: Urgent need for clinical trials.
International Forum of Allergy & Rhinology
, 13
(8)
pp. 1558-1560.
10.1002/alr.23100.
|
|
Lechner, Matt;
Takahashi, Yoko;
Turri-Zanoni, Mario;
Ferrari, Marco;
Liu, Jacklyn;
Counsell, Nicholas;
Mattavelli, Davide;
... Hanna, Ehab Y; + view all
(2023)
International Multicenter Study of Clinical Outcomes of Sinonasal Melanoma Shows Survival Benefit for Patients Treated with Immune Checkpoint Inhibitors and Potential Improvements to the Current TNM Staging System.
Journal of Neurological Surgery Part B: Skull Base
, 84
(4)
pp. 307-319.
10.1055/s-0042-1750178.
|
|
Lechner, M;
Counsell, N;
Liu, J;
Eynon-Lewis, N;
Paun, S;
Lund, VJ;
Jayaraj, S;
(2020)
Anosmia and hyposmia in health-care workers with undiagnosed SARS-CoV-2 infection.
Lancet Microbe
, 1
(4)
, Article e150. 10.1016/S2666-5247(20)30096-3.
|
|
|
Ledermann, JA;
(2022)
Testing for homologous recombination deficiency – does it provide new insights for the use of veliparib?
Gynecologic Oncology
, 164
(2)
pp. 243-244.
10.1016/j.ygyno.2022.01.018.
|
|
Ledermann, JA;
Zurawski, B;
Raspagliesi, F;
De Giorgi, U;
Arranz Arija, J;
Romeo Marin, M;
Lisyanskaya, A;
... Sehouli, J; + view all
(2021)
Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study.
ESMO Open
, 7
(1)
, Article 100311. 10.1016/j.esmoop.2021.100311.
|
|
|
Ledermann, JA;
(2019)
Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?
[Editorial comment].
Gynecologic Oncology
, 153
(2)
pp. 213-214.
10.1016/j.ygyno.2019.04.014.
|
|
Ledermann, JA;
(2019)
Extending the scope of PARP inhibitors in ovarian cancer.
[Editorial comment].
The Lancet Oncology
, 20
(4)
pp. 470-472.
10.1016/S1470-2045(19)30019-1.
|
|
Ledermann, JA;
(2018)
First-line treatment of ovarian cancer: questions and controversies to address.
Therapeutic Advances in Medical Oncology
, 10
pp. 1-8.
10.1177/1758835918768232.
|
|
Ledermann, JA;
(2017)
Front-line therapy of advanced ovarian cancer: new approaches.
Annals of Oncology
, 28
(Suppl. 8)
viii46-viii50.
10.1093/annonc/mdx452.
|
|
Ledermann, JA;
(2016)
PARP inhibitors in ovarian cancer.
Annals of Oncology
, 27
(Suppl 1)
i40-i44.
10.1093/annonc/mdw094.
|
|
Ledermann, JA;
Drew, Y;
Kristeleit, RS;
(2016)
Homologous recombination deficiency and ovarian cancer.
European Journal of Cancer
, 60
pp. 49-58.
10.1016/j.ejca.2016.03.005.
|
|
Ledermann, JA;
Embleton, AC;
Raja, F;
Perren, TJ;
Jayson, GC;
Rustin, GJS;
Kaye, SB;
... Collaborators, I; + view all
(2016)
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet
, 387
(10023)
pp. 1066-1074.
10.1016/S0140-6736(15)01167-8.
|
|
Ledermann, JA;
Embleton-Thirsk, AC;
Perren, TJ;
Jayson, GC;
Rustin, GJS;
Kaye, SB;
Hirte, H;
... ICON6 collaborators, .; + view all
(2021)
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.
ESMO Open
, 6
(2)
, Article 100043. 10.1016/j.esmoop.2020.100043.
|
|
|
Ledermann, JA;
Harter, P;
Gourley, C;
Friedlander, M;
Vergote, I;
Rustin, G;
Scott, C;
... Matulonis, U; + view all
(2016)
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.
British Journal of Cancer
, 115
(11)
pp. 1313-1320.
10.1038/bjc.2016.348.
|
|
Ledermann, JA;
Harter, P;
Gourley, C;
Friedlander, M;
Vergote, I;
Rustin, G;
Scott, C;
... Matulonis, U; + view all
(2016)
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
The Lancet Oncology
, 17
(11)
pp. 1579-1589.
10.1016/S1470-2045(16)30376-X.
|
|
Ledermann, JA;
Oza, AM;
Lorusso, D;
Aghajanian, C;
Oaknin, A;
Dean, A;
Colombo, N;
... Coleman, RL; + view all
(2020)
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Lancet Oncology
, 21
(5)
pp. 710-722.
10.1016/S1470-2045(20)30061-9.
|
|
Ledermann, JA;
Pujade-Lauraine, E;
(2019)
Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer.
Therapeutic Advances in Medical Oncology
, 11
pp. 1-18.
10.1177/1758835919849753.
|
|
|
Lee, CK;
Friedlander, ML;
Tjokrowidjaja, A;
Ledermann, JA;
Coleman, RL;
Mirza, MR;
Matulonis, UA;
... Scott, CL; + view all
(2021)
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Cancer
, 127
(14)
pp. 2432-2441.
10.1002/cncr.33517.
|
|
Lee, Siow Ming;
Hewish, Madeleine;
Ahmed, Samreen;
Papadatos-Pastos, Dionysis;
Karapanagiotou, Eleni;
Blackhall, Fiona;
Ford, Amy;
... Hackshaw, Allan; + view all
(2025)
Hydroxychloroquine in combination with platinum doublet chemotherapy as first-line treatment for extensive-stage small cell lung cancer (Study 15): A randomised phase II multicentre trial.
European Journal of Cancer
, 215
, Article 115162. 10.1016/j.ejca.2024.115162.
|
|
Lee, Yeh Chen;
King, Madeleine T;
O'Connell, Rachel L;
Lanceley, Anne;
Joly, Florence;
Hilpert, Felix;
Davis, Alison;
... GCIG Symptom Benefit Group, .; + view all
(2022)
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study.
International Journal of Gynecologic Cancer
10.1136/ijgc-2021-003142.
(In press).
|
|
Lee, A;
(2020)
Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer.
Cancer Discovery
, 10
(10)
pp. 1465-1474.
10.1158/2159-8290.CD-20-0773.
|
|
Lee, LYW;
Cazier, J-B;
Starkey, T;
Briggs, SEW;
Arnold, R;
Bisht, V;
Booth, S;
... UK Coronavirus Cancer Monitoring Project Team; + view all
(2020)
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study.
The Lancet Oncology
, 21
(10)
pp. 1309-1316.
10.1016/S1470-2045(20)30442-3.
|
|
Lee, SM;
Falzon, M;
Blackhall, F;
Spicer, J;
Nicolson, M;
Chaudhuri, A;
Middleton, G;
... Hackshaw, A; + view all
(2016)
Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET).
Journal of Clinical Oncology
, 35
(4)
pp. 402-411.
10.1200/JCO.2016.68.1841.
|
|
|
Lee, SM;
Hackshaw, A;
(2013)
A potential new enriching trial design for selecting non-small-cell lung cancer patients with no predictive biomarker for trials based on both histology and early tumor response: further analysis of a thalidomide trial.
Cancer Medicine
, 2
(3)
360 -366.
10.1002/cam4.74.
|
|
|
Lee, SM;
Upadhyay, S;
Lewanski, C;
Falk, S;
Skailes, G;
Woll, PJ;
Hatton, M;
... Hackshaw, A; + view all
(2019)
The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy.
European Journal of Cancer
, 120
pp. 86-96.
10.1016/j.ejca.2019.07.025.
|
|
|
Lemech, CR;
Ensell, L;
Paterson, JC;
Eminowicz, G;
Lowe, H;
Arora, R;
Arkenau, H-T;
... Kristeleit, RS; + view all
(2016)
Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer.
Oncology
, 91
(1)
pp. 48-54.
10.1159/000445999.
|
|
Lheureux, S;
Lai, Z;
Dougherty, BA;
Runswick, S;
Hodgson, DR;
Timms, KM;
Lanchbury, JS;
... Oza, AM; + view all
(2017)
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
Clinical Cancer Research
, 23
(15)
pp. 4086-4094.
10.1158/1078-0432.CCR-16-2615.
|
|
Lim, EL;
Trinh, DL;
Ries, RE;
Wang, J;
Gerbing, RB;
Ma, Y;
Topham, J;
... Marra, MA; + view all
(2017)
MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia.
Journal of Clinical Oncology
, 35
(35)
pp. 3964-3977.
10.1200/JCO.2017.74.7451.
|
 |
|
Linch, M;
Goh, G;
Hiley, C;
Shanmugabavan, Y;
McGranahan, N;
Rowan, A;
Wong, YNS;
... Swanton, C; + view all
(2017)
Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters.
Annals of Oncology
, 28
(10)
pp. 2472-2480.
10.1093/annonc/mdx355.
|
|
Litchfield, K;
Reading, JL;
Lim, EL;
Xu, H;
Liu, P;
Al-Bakir, M;
Wong, YNS;
... Swanton, C; + view all
(2020)
Escape from nonsense-mediated decay associates with anti-tumor immunogenicity.
Nature Communications
, 11
, Article 3800. 10.1038/s41467-020-17526-5.
|
|
|
Litchfield, K;
Stanislaw, S;
Spain, L;
Gallegos, LL;
Rowan, A;
Schnidrig, D;
Rosenbaum, H;
... Turajlic, S; + view all
(2020)
Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue.
Cell Reports
, 31
(5)
p. 107550.
10.1016/j.celrep.2020.107550.
|
|
López, S;
Lim, EL;
Horswell, S;
Haase, K;
Huebner, A;
Dietzen, M;
Mourikis, TP;
... McGranahan, N; + view all
(2020)
Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution.
Nature Genetics
, 52
(3)
pp. 283-293.
10.1038/s41588-020-0584-7.
|
|
Lucas, Olivia;
Ward, Sophia;
Zaidi, Rija;
Bunkum, Abigail;
Frankell, Alexander M;
Moore, David A;
Hill, Mark S;
... Zaccaria, Simone; + view all
(2024)
Characterizing the evolutionary dynamics of cancer proliferation in single-cell clones with SPRINTER.
Nature Genetics
10.1038/s41588-024-01989-z.
(In press).
|
|
|
Luminari, S;
Fossa, A;
Trotman, J;
Molin, D;
D'Amore, F;
Enblad, G;
Berkahn, L;
... Johnson, PWM; + view all
(2024)
Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial.
Journal of Clinical Oncology
, 42
(1)
pp. 13-18.
10.1200/JCO.23.01177.
|
M
|
Mak, Ka-Man;
McDonald, Fiona;
Teague, Jonathan;
Faivre-Finn, Corinne;
Forster, Martin;
Hanna, Gerard;
Moinuddin, Syed;
... Saron, TMG; + view all
(2022)
SARON: stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer (NSCLC).
Presented at: 20th Annual British Thoracic Oncology Group Conference 2022, Virtual.
|
|
Malone, FD;
Canick, JA;
Ball, RH;
Nyberg, DA;
Comstock, CH;
Bukowski, R;
Berkowitz, RL;
... FASTER Res Consortium; + view all
(2005)
First-trimester or second-trimester screening, or both, for Down's syndrome.
NEW ENGL J MED
, 353
(19)
2001 - 2011.
|
|
|
Mandair, D;
Khan, MS;
Lopes, A;
Furtado O'Mahony, L;
Ensell, L;
Lowe, H;
Hartley, JA;
... Meyer, T; + view all
(2021)
Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors.
Journal of Clinical Endocrinology and Metabolism
, 106
(3)
pp. 872-882.
10.1210/clinem/dgaa822.
|
|
Marchetti, C;
Kristeleit, R;
McCormack, M;
Mould, T;
Olaitan, A;
Widschwendter, M;
MacDonald, N;
(2017)
Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review.
Gynecologic Oncology
, 144
(1)
pp. 57-60.
10.1016/j.ygyno.2016.11.001.
|
|
Marth, C;
Tarnawski, R;
Tyulyandina, A;
Pignata, S;
Gilbert, L;
Kaen, D;
Rubio, MJ;
... Makker, V; + view all
(2022)
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
International journal of gynecological cancer: official journal of the International Gynecological Cancer Society
, 32
(1)
pp. 93-100.
10.1136/ijgc-2021-003017.
|
|
|
Martinez-Calle, N;
Kirkwood, AA;
Lamb, M;
Smith, A;
Khwaja, J;
Manos, K;
Shrubsole, C;
... Fox, CP; + view all
(2021)
Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.
Advances in Therapy
10.1007/s12325-021-01764-0.
|
|
|
Mateo, J;
Moreno, V;
Gupta, A;
Kaye, SB;
Dean, E;
Middleton, MR;
Friedlander, M;
... Molife, LR; + view all
(2016)
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.
Targeted Oncology
, 11
(3)
pp. 401-415.
10.1007/s11523-016-0435-8.
|
|
Mato, AR;
Roeker, LE;
Eyre, TA;
Nabhan, C;
Lamanna, N;
Hill, BT;
Brander, DM;
... Fox, CP; + view all
(2019)
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.
Blood Advances
, 3
(10)
pp. 1568-1573.
10.1182/bloodadvances.2019000180.
|
|
|
Mattes, FM;
Hainsworth, EG;
Geretti, AM;
Nebbia, G;
Prentice, G;
Potter, M;
Burroughs, AK;
... Griffiths, PD; + view all
(2004)
A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients.
J INFECT DIS
, 189
(8)
1355 - 1361.
|
|
|
Matulonis, UA;
Shapira-Frommer, R;
Santin, AD;
Lisyanskaya, AS;
Pignata, S;
Vergote, I;
Raspagliesi, F;
... Ledermann, JA; + view all
(2019)
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
Annals of Oncology
, 30
(7)
pp. 1080-1087.
10.1093/annonc/mdz135.
|
|
Matulonis, UA;
Walder, L;
Nøttrup, TJ;
Bessette, P;
Mahner, S;
Gil-Martin, M;
Kalbacher, E;
... Mirza, MR; + view all
(2019)
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.
Journal of Clinical Oncology
, 37
(34)
pp. 3183-3191.
10.1200/JCO.19.00917.
|
|
|
Mauro, Ezequiel;
de Castro, Tiago;
Zeitlhoefler, Marcus;
Hackshaw, Allan;
Lee, MinJae;
Meyer, Tim;
Singal, Amit G;
(2025)
Strategies to address non-proportional hazards between survival curves - Lessons from phase III trials in hepatocellular carcinoma.
Journal of Hepatology
10.1016/j.jhep.2025.08.042.
(In press).
|
|
|
McCormack, Mary;
Eminowicz, Gemma;
Gallardo, Dolores;
Diez, Patricia;
Farrelly, Laura;
Kent, Christopher;
Hudson, Emma;
... Ledermann, Jonathan Andrew; + view all
(2024)
Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial.
The Lancet
, 404
(10462)
pp. 1525-1535.
10.1016/S0140-6736(24)01438-7.
|
|
McCormack, M;
Kadalayil, L;
Hackshaw, A;
Hall-Craggs, MA;
Symonds, RP;
Warwick, V;
Simonds, H;
... Ledermann, JA; + view all
(2013)
A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer.
British Journal of Cancer
, 108
(12)
2464 -2469.
10.1038/bjc.2013.230.
|
|
|
McCulloch, R;
Lewis, D;
Crosbie, N;
Eyre, TA;
Bolam, S;
Arasaretnam, A;
Creasey, T;
... Rule, S; + view all
(2021)
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
British Journal of Haematology
10.1111/bjh.17363.
|
|
|
McGranahan, N;
Rosenthal, R;
Hiley, CT;
Rowan, AJ;
Watkins, TBK;
Wilson, GA;
Birkbak, NJ;
... Swanton, C; + view all
(2017)
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.
Cell
10.1016/j.cell.2017.10.001.
(In press).
|
|
|
McGregor, L;
Von Wagner, C;
Atkin, W;
Kralj-Hans, I;
Halloran, S;
Handley, G;
Logan, R;
... Wardle, J; + view all
(2016)
Reducing the social gradient in uptake of the NHS Colorectal Cancer Screening Programme using a narrative-based information leaflet: a cluster-randomised trial.
Gastroenterology Research and Practice
, 2016
, Article 3670150. 10.1155/2016/3670150.
|
|
McLeavy, L;
Rahman, B;
Kristeleit, R;
Ledermann, J;
Lockley, M;
McCormack, M;
Mould, T;
... Lanceley, A; + view all
(2020)
Mainstreamed Genetic Testing in Ovarian Cancer: Patient Experience of the Testing Process.
International Journal of Gynecological Cancer
, 30
(2)
pp. 221-226.
10.1136/ijgc-2019-000630.
|
|
McMillan, AK;
Phillips, EH;
Kirkwood, AA;
Barrans, S;
Burton, C;
Rule, S;
Patmore, R;
... Linch, DC; + view all
(2020)
Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial.
Annals of Oncology
10.1016/j.annonc.2020.05.016.
(In press).
|
|
|
McNamara, MG;
Bridgewater, J;
Lopes, A;
Wasan, H;
Malka, D;
Jensen, LH;
Okusaka, T;
... Valle, JW; + view all
(2017)
Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials.
BMC Cancer
, 17
, Article 262. 10.1186/s12885-017-3266-9.
|
|
|
McNamara, MG;
Lopes, A;
Wasan, H;
Malka, D;
Goldstein, D;
Shannon, J;
Okusaka, T;
... Valle, JW; + view all
(2020)
Landmark survival analysis and impact of anatomic origin in prospective clinical trials of biliary tract cancer.
Journal of Hepatology
, 73
(5)
pp. 1109-1117.
10.1016/j.jhep.2020.05.014.
|
|
Megias, D;
Phillips, M;
Clifton-Hadley, L;
Harron, E;
Eaton, DJ;
Sanghera, P;
Whitfield, G;
(2017)
Dose specification for hippocampal sparing whole brain radiotherapy (HS WBRT): considerations from the UK HIPPO trial QA programme.
British Journal Of Radiology
, 90
(1071)
, Article 20160829. 10.1259/bjr.20160829.
|
|
|
Meyer, Tim;
Galani, Sevasti;
Lopes, Andre;
Vogel, Arndt;
(2023)
Aetiology of liver disease and response to immune checkpoint inhibitors: an updated meta-analysis confirms benefit in those with non-viral liver disease.
Journal of Hepatology
, 79
(2)
e73-e76.
10.1016/j.jhep.2023.04.012.
|
|
Michael, Agnieszka;
Wilson, William;
Sunshine, Sunny;
Annels, Nicola;
Harrop, Richard;
Blount, Daniel;
Pandha, Hardev;
... Ledermann, Jonathan; + view all
(2024)
A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC).
International Journal of Gynecologic Cancer
10.1136/ijgc-2023-005200.
(In press).
|
|
Mikhaeel, NG;
Cunningham, D;
Counsell, N;
McMillan, A;
Radford, JA;
Ardeshna, KM;
Lawrie, A;
... Barrington, SF; + view all
(2021)
FDG‐PET/CT after two cycles of R‐CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study.
British Journal of Haematology
, 192
(3)
pp. 504-513.
10.1111/bjh.16875.
|
|
Milani, A;
Kristeleit, R;
McCormack, M;
Raja, F;
Luvero, D;
Widschwendter, M;
MacDonald, N;
... Ledermann, JA; + view all
(2017)
Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy.
ESMO Open
, 1
(6)
, Article e000117. 10.1136/esmoopen-2016-000117.
|
|
Miller, RE;
Leary, A;
Scott, CL;
Serra, V;
Lord, CJ;
Bowtell, D;
Chang, DK;
... Yates, LR; + view all
(2020)
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
Annals of Oncology
, 31
(12)
pp. 1606-1622.
10.1016/j.annonc.2020.08.2102.
|
|
|
Miller, R;
Devlin, M-J;
Brown, NF;
Grunewald, T;
McCormack, M;
Lockley, M;
Ledermann, JA;
... Kristeleit, RS; + view all
(2017)
Outcome of patients with advanced endometrial and cervical cancer treated in a phase 1 unit.
Presented at: 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, USA.
|
|
|
Miller, RE;
Crusz, SM;
Ledermann, JA;
(2019)
Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?
Future Oncology
, 15
(16)
pp. 1845-1853.
10.2217/fon-2019-0057.
|
|
Miller, RE;
Devlin, M;
Brown, N;
Woo, K;
Grunewald, T;
Speirs, A;
Mitchison, M;
... Kristeleit, R; + view all
(2017)
Guidance by molecular selection improves the outcome of early phase treatment for gynecological (GYN) cancers.
Presented at: AACR Annual Meeting 2017, Washington, D.C., USA.
|
|
Miller, RE;
Ledermann, JA;
(2017)
The European Society for Medical Oncology (ESMO) Congress 2016: Highlights and summary of selected abstracts in gynecologic cancers.
Gynecologic Oncology
, 144
(1)
pp. 8-10.
10.1016/j.ygyno.2016.11.040.
|
|
Miller, RE;
Ledermann, JA;
(2016)
The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
Clinical Advances in Hematology & Oncology
, 14
(8)
pp. 619-627.
|
|
|
Miller, RE;
Ledermann, JA;
(2016)
The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
Clinical Advances in Hematology & Oncology
, 14
(9)
pp. 704-711.
|
|
Mirza, MR;
Benigno, B;
Dørum, A;
Mahner, S;
Bessette, P;
Barceló, IB;
Berton-Rigaud, D;
... Matulonis, UA; + view all
(2020)
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Gynecologic Oncology
10.1016/j.ygyno.2020.09.006.
(In press).
|
|
|
Mirza, MR;
Monk, BJ;
Herrstedt, J;
Oza, AM;
Mahner, S;
Redondo, A;
Fabbro, M;
... ENGOT-OV16/NOVA Investigators; + view all
(2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
The New England Journal of Medicine
, 375
(22)
pp. 2154-2164.
10.1056/NEJMoa1611310.
|
|
Mirza, MR;
Pignata, S;
Ledermann, JA;
(2018)
Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
Annals of Oncology
, 29
(6)
pp. 1366-1376.
10.1093/annonc/mdy174.
|
|
Mitchell, RJ;
Kirkwood, AA;
Barretta, E;
Clifton-Hadley, L;
Lawrie, E;
Lee, S;
Leongamornlert, D;
... Fielding, AK; + view all
(2021)
IKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial.
Blood Advances
, 5
(17)
pp. 3322-3332.
10.1182/bloodadvances.2021004430.
|
|
|
Mitchell, E;
Goodman, K;
Hartley, S;
Hickey, H;
McDonald, AM;
Meadows, HM;
Rhodes, S;
... UK Trial Managers’ Network Executive Group; + view all
(2020)
Where do we go from here? – Opportunities and barriers to the career development of trial managers: a survey of UK-based trial management professionals.
Trials
, 21
, Article 384. 10.1186/s13063-020-04316-z.
|
|
|
Monk, BJ;
Colombo, N;
Oza, AM;
Fujiwara, K;
Birrer, MJ;
Randall, L;
Poddubskaya, EV;
... Ledermann, JA; + view all
(2021)
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
The Lancet Oncology
, 22
(9)
pp. 1275-1289.
10.1016/S1470-2045(21)00342-9.
|
|
Moorman, Anthony;
Butler, Ellie;
Barretta, Emilio;
Kirkwood, Amy A;
Schwab, Claire;
Creasey, Thomas;
Leongamornlert, Daniel A;
... Enshaei, Amir; + view all
(2021)
Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study.
Leukemia
10.1038/s41375-021-01448-2.
(In press).
|
|
|
Moorman, AV;
Schwab, C;
Winterman, E;
Hancock, J;
Castleton, A;
Cummins, M;
Gibson, B;
... Vora, A; + view all
(2020)
Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL‐class fusion.
British Journal of Haematology
10.1111/bjh.17093.
(In press).
|
|
|
Morgan, RD;
McNeish, IA;
Cook, AD;
James, EC;
Lord, R;
Dark, G;
Glasspool, RM;
... Clamp, AR; + view all
(2021)
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
The Lancet Oncology
, 22
(2)
pp. 277-288.
10.1016/S1470-2045(20)30591-X.
|
|
|
Mossop, H;
Walmsley, Z;
Wilson, N;
Agbeleye, O;
Bardgett, M;
Bevin-Nicholls, A;
Breckons, M;
... Wason, JMS; + view all
(2025)
Practical guidance for conducting high-quality and rapid interim analyses in adaptive clinical trials.
BMC Medicine
, 23
, Article 528. 10.1186/s12916-025-04362-x.
|
|
N
|
Nageswaran, Gayathri;
Byrne, Suzanne;
Veeriah, Selvaraju;
Chain, Benny;
(2022)
The Intra-Tumoral T Cell Receptor Repertoire: Steps Towards a Useful Clinical Biomarker.
Methods in Molecular Biology
, 2574
pp. 135-158.
10.1007/978-1-0716-2712-9_6.
|
|
Newbold, K;
Armstrong, N;
Beasley, M;
Farnell, K;
Garcez, K;
Hassan, F;
Iqbal, S;
... Mallick, U; + view all
(2025)
Iodine or Not for Low-risk Differentiated Thyroid Cancer: How Should We Implement the Findings into UK Practice? An Expert Consensus Opinion.
Clinical Oncology
, 48
, Article 103954. 10.1016/j.clon.2025.103954.
|
|
Newton, C;
Murali, K;
Ahmad, A;
Hockings, H;
Graham, R;
Liberale, V;
Sarker, S-J;
... Lockley, M; + view all
(2019)
A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice.
European Journal of Cancer
, 113
pp. 19-27.
10.1016/j.ejca.2019.03.001.
|
|
|
Newton, C;
Nordin, A;
Rolland, P;
Ind, T;
Larsen-Disney, P;
Martin-Hirsch, P;
Beaver, K;
... Fotopoulou, C; + view all
(2020)
British Gynaecological Cancer Society recommendations and guidance on patient-initiated follow-up (PIFU).
International Journal of Gynecologic Cancer
, 30
(5)
pp. 695-700.
10.1136/ijgc-2019-001176.
|
|
|
Ng, Kevin W;
Boumelha, Jesse;
Enfield, Katey SS;
Almagro, Jorge;
Cha, Hongui;
Pich, Oriol;
Karasaki, Takahiro;
... Kassiotis, George; + view all
(2023)
Antibodies against endogenous retroviruses promote lung cancer immunotherapy.
Nature
10.1038/s41586-023-05771-9.
(In press).
|
O
|
O'Connor, MN;
Kallenberg, DM;
Camilli, C;
Pilotti, C;
Dritsoula, A;
Jackstadt, R;
Bowers, CE;
... Greenwood, J; + view all
(2021)
LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency.
Med
, 2
(11)
1231-1252.e10.
10.1016/j.medj.2021.10.002.
|
|
O'Reilly, MA;
Govender, D;
Kirkwood, AA;
Vora, A;
Samarasinghe, S;
Khwaja, A;
Grandage, V;
... O'Connor, D; + view all
(2019)
The incidence of invasive fungal infections in children, adolescents and young adults with acute lymphoblastic leukaemia/lymphoma treated with the UKALL2011 protocol: a multicentre retrospective study.
[Letter].
British Journal of Haematology
, 186
(2)
pp. 327-329.
10.1111/bjh.15798.
|
|
Oaknin, A;
Oza, AM;
Lorusso, D;
Aghajanian, C;
Dean, A;
Colombo, N;
Weberpals, JI;
... Coleman, RL; + view all
(2021)
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.
Cancer Medicine
10.1002/cam4.4260.
(In press).
|
|
|
Orlando, Francesco;
Romanel, Alessandro;
Trujillo, Blanca;
Sigouros, Michael;
Wetterskog, Daniel;
Quaini, Orsetta;
Leone, Gianmarco;
... Demichelis, Francesca; + view all
(2022)
Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay.
NAR Cancer
, 4
(2)
, Article zcac016. 10.1093/narcan/zcac016.
|
|
Orrell, M;
Yates, L;
Leung, P;
Kang, S;
Hoare, Z;
Whitaker, C;
Burns, A;
... Orgeta, V; + view all
(2017)
The impact of individual Cognitive Stimulation Therapy (iCST) on cognition, quality of life, caregiver health, and family relationships in dementia: A randomised controlled trial.
PLoS Medicine
, 14
(3)
, Article e1002269. 10.1371/journal.pmed.1002269.
|
|
Oza, AM;
Cook, AD;
Pfisterer, J;
Embleton, A;
Ledermann, JA;
Pujade-Lauraine, E;
Kristensen, G;
... ICON7, trial investigators; + view all
(2015)
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Lancet Oncology
, 16
(8)
pp. 928-936.
10.1016/S1470-2045(15)00086-8.
|
|
|
Oza, AM;
Lorusso, D;
Aghajanian, C;
Oaknin, A;
Dean, A;
Colombo, N;
Weberpals, JI;
... Coleman, RL; + view all
(2020)
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
Journal of Clinical Oncology
10.1200/JCO.19.03107.
(In press).
|
 |
P
|
Pallmann, P;
Sydes, MR;
Other authors, M;
(2018)
Adaptive designs in clinical trials: why use them, and how to run and report them.
BMC Medicine
, 16
, Article 29. 10.1186/s12916-018-1017-7.
|
|
Pan, Xiaoxi;
AbdulJabbar, Khalid;
Coelho-Lima, Jose;
Grapa, Anca-Ioana;
Zhang, Hanyun;
Cheung, Alvin Ho Kwan;
Baena, Juvenal;
... Moore, David A; + view all
(2024)
The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma.
Nature Cancer
10.1038/s43018-023-00694-w.
|
|
Papaccio, F;
García-Mico, B;
Gimeno-Valiente, F;
Cabeza-Segura, M;
Gambardella, V;
Gutiérrez-Bravo, MF;
Alfaro-Cervelló, C;
... Castillo, J; + view all
(2023)
“Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction”.
Journal of Experimental & Clinical Cancer Research
, 42
(1)
, Article 8. 10.1186/s13046-022-02591-z.
|
|
|
Patel, Alpa V;
Chang, Ellen T;
Hackshaw, Allan;
Janes, Sam M;
Buist, Diana SM;
Hubbell, Earl;
Clarke, Christina A;
(2024)
Overall and non-lung cancer incidence and mortality in the National Lung Screening Trial: Opportunities for multi-cancer early detection.
Cancer Medicine
, 13
(12)
, Article e7414. 10.1002/cam4.7414.
|
|
Patel, B;
Kirkwood, AA;
Dey, A;
Marks, DI;
McMillan, AK;
Menne, TF;
Micklewright, L;
... Fielding, AK; + view all
(2016)
Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial.
Leukemia
10.1038/leu.2016.219.
|
|
Pawsey, A;
Mahalingam, P;
Senthivel, N;
Ramessur, A;
Turnbull, E;
Usman, S;
Browne, R;
... Eminowicz, G; + view all
(2025)
Real World Outcomes in Patients With Recurrent, Advanced, or Metastatic Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab.
Clinical Oncology
, 37
, Article 103656. 10.1016/j.clon.2024.10.008.
|
|
Perna, C;
Eminowicz, G;
Asghar, U;
Imseeh, G;
Kirkwood, A;
Mitra, A;
Arora, R;
... McCormack, M; + view all
(2016)
Uterine carcinosarcoma: a retrospective clinical cohort analysis.
Presented at: ESMO 2016: 41st ESMO Congress, Copenhagen, Denmark.
|
|
Petit, C;
Lacas, B;
Pignon, J-P;
Le, QT;
Grégoire, V;
Grau, C;
Hackshaw, A;
... MACH-NC and MARCH Collaborative Groups; + view all
(2021)
Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis.
Lancet Oncology
, 22
(5)
pp. 727-736.
10.1016/S1470-2045(21)00076-0.
|
|
Phillips, EH;
Lannon, M;
Lopes, A;
Chadwick, H;
Jones, G;
Sieniawski, M;
Davies, A;
... Lennard, A; + view all
(2019)
High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II Study.
[Letter].
Bone Marrow Transplantation
, 54
pp. 465-468.
10.1038/s41409-018-0294-2.
|
|
Phillips, EH;
Nash, S;
Adedayo, T;
Whelan, CJ;
Fontana, M;
Mahmood, S;
Lachmann, HJ;
... Wechalekar, AD; + view all
(2017)
Pitfalls in conducting prospective trials in stage III cardiac amyloidosis - experience from the REVEAL study.
Amyloid
, 24
(4)
pp. 250-252.
10.1080/13506129.2017.1385453.
|
|
Pilotti, C;
Greenwood, J;
Moss, SE;
(2020)
Functional Evaluation of AMD-Associated Risk Variants of Complement Factor B.
Investigative Opthalmology & Visual Science
, 61
(5)
, Article 19. 10.1167/iovs.61.5.19.
|
|
|
Pilotti, Camilla;
(2018)
Complement Factor B and pathological angiogenesis in age-related macular degeneration.
Doctoral thesis (Ph.D), UCL (University College London).
|
|
Pinato, DJ;
Aguilar-Company, J;
Ferrante, D;
Hanbury, G;
Bower, M;
Salazar, R;
Mirallas, O;
... Chester, J; + view all
(2022)
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study.
The Lancet Oncology
, 23
(7)
pp. 865-875.
10.1016/S1470-2045(22)00273-X.
|
|
Pinato, DJ;
Scotti, L;
Gennari, A;
Colomba-Blameble, E;
Dolly, S;
Loizidou, A;
Chester, J;
... Cortellini, A; + view all
(2021)
Determinants of enhanced vulnerability to COVID-19 in UK cancer patients: a European Study.
European Journal of Cancer
, 150
pp. 190-202.
10.1016/j.ejca.2021.03.035.
|
|
Pinato, DJ;
Tabernero, J;
Bower, M;
Scotti, L;
Patel, M;
Colomba, E;
Dolly, S;
... Iglesias, M; + view all
(2021)
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study.
The Lancet Oncology
10.1016/s1470-2045(21)00573-8.
(In press).
|
|
|
Pinato, DJ;
Lee, AJX;
Biello, F;
Seguí, E;
Aguilar-Company, J;
Carbó, A;
Bruna, R;
... Gennari, A; + view all
(2020)
Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe.
Cancers
, 12
(7)
, Article 1841. 10.3390/cancers12071841.
|
|
|
Popat, R;
Counsell, N;
De Tute, R;
De-Silva, D;
Phillips, EH;
Cavenagh, JD;
Adedayo, T;
... Yong, K; + view all
(2021)
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial.
British Journal of Haematology
, 193
(3)
e19-e22.
10.1111/bjh.17391.
|
|
Popat, Sanjay;
Januszewski, Adam;
O'Brien, Mary;
Ahmad, Tanya;
Lewanski, Conrad;
Dernedde, Ulrike;
Jankowska, Petra;
... Wilson, William; + view all
(2024)
Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy.
British Journal of Cancer
10.1038/s41416-024-02901-6.
(In press).
|
|
Post, CCB;
De Boer, SM;
Powell, ME;
Mileshkin, L;
Katsaros, D;
Bessette, P;
Haie-Meder, C;
... Creutzberg, CL; + view all
(2021)
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial.
International Journal of Radiation Oncology - Biology - Physics
, 109
(4)
pp. 975-986.
10.1016/j.ijrobp.2020.10.030.
|
|
Poveda, A;
Floquet, A;
Ledermann, JA;
Asher, R;
Penson, RT;
Oza, AM;
Korach, J;
... SOLO2/ENGOT-Ov21 investigators, .; + view all
(2021)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
The Lancet Oncology
, 22
(5)
pp. 620-631.
10.1016/S1470-2045(21)00073-5.
|
|
Poveda, A;
Lheureux, S;
Colombo, N;
Cibula, D;
Lindemann, K;
Weberpals, J;
Bjurberg, M;
... Škof, E; + view all
(2022)
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
Gynecologic Oncology
10.1016/j.ygyno.2021.12.025.
(In press).
|
|
Provencher, DM;
Gallagher, CJ;
Parulekar, WR;
Ledermann, JA;
Armstrong, DK;
Brundage, M;
Gourley, C;
... MacKay, HJ; + view all
(2018)
OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.
Annals of Oncology
, 29
(2)
pp. 431-438.
10.1093/annonc/mdx754.
|
|
Pujade-Lauraine, E;
Fujiwara, K;
Ledermann, JA;
Oza, AM;
Kristeleit, R;
Ray-Coquard, I-L;
Richardson, GE;
... Monk, BJ; + view all
(2021)
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
The Lancet Oncology
, 22
(7)
pp. 1034-1046.
10.1016/S1470-2045(21)00216-3.
|
|
Pujade-Lauraine, Eric;
Fujiwara, Keiichi;
Ledermann, Jonathan A;
Oza, Amit M;
Kristeleit, Rebecca;
Ray-Coquard, Isabelle-Laure;
Richardson, Gary E;
... Monk, Bradley J; + view all
(2021)
Avelumab Alone or in Combination With Chemotherapy Versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): An Open-Label, Three-Arm, Randomised, Phase 3 Study.
Obstetrical & Gynecological Survey
, 76
(11)
pp. 673-675.
10.1097/OGX.0000000000000980.
|
|
Pujade-Lauraine, E;
Ledermann, JA;
Selle, F;
Gebski, V;
Penson, RT;
Oza, AM;
Korach, J;
... SOLO2/ENGOT-Ov21 Investigators, .; + view all
(2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
The Lancet Oncology
, 18
(9)
pp. 1274-1284.
10.1016/S1470-2045(17)30469-2.
|
|
Puttick, Clare;
Jones, Thomas P;
Leung, Michelle M;
Galvez-Cancino, Felipe;
Liu, Jiali;
Varas-Godoy, Manuel;
Rowan, Andrew;
... Mcgranahan, Nicholas; + view all
(2024)
MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution.
Nature Genetics
, 56
(10)
pp. 2121-2131.
10.1038/s41588-024-01883-8.
|
|
Q
|
Quaife, SL;
Waller, J;
Dickson, JL;
Brain, KE;
Kurtidu, C;
McCabe, J;
Hackshaw, A;
... Janes, SM; + view all
(2021)
Psychological Targets for Lung Cancer Screening Uptake: A Prospective Longitudinal Cohort Study.
Journal of Thoracic Oncology
, 16
(12)
pp. 2016-2028.
10.1016/j.jtho.2021.07.025.
|
R
|
Rahman, B;
Lanceley, A;
Kristeleit, R;
Ledermann, J;
Lockley, M;
McCormack, M;
Mould, T;
(2019)
Mainstreamed genetic testing for women with ovarian cancer: first-year experience.
Journal of Medical Genetics
, 56
(3)
pp. 195-198.
10.1136/jmedgenet-2017-105140.
|
|
Raine, R;
Atkin, W;
Von Wagner, C;
Duffy, S;
Kralj-Hans, I;
Hackshaw, A;
Counsell, N;
... Wardle, J; + view all
(2017)
Testing innovative strategies to reduce the social gradient in the uptake of bowel cancer screening: a programme of four qualitatively enhanced randomised controlled trial.
Programme Grants for Applied Research
, 5
(8)
10.3310/pgfar05080.
|
|
|
Raine, R;
Duffy, SW;
Wardle, J;
Solmi, F;
Morris, S;
Howe, R;
Kralj-Hans, I;
... Atkin, W; + view all
(2016)
Impact of general practice endorsement on the social gradient in uptake in bowel cancer screening.
British Journal of Cancer
, 114
pp. 321-326.
10.1038/bjc.2015.413.
|
|
Raine, R;
Moss, SM;
von Wagner, C;
Atkin, W;
Hans, IK;
Howe, R;
Solmi, F;
... Duffy, SW; + view all
(2016)
A national cluster-randomised controlled trial to examine the effect of enhanced reminders on the socioeconomic gradient in uptake in bowel cancer screening.
British Journal of Cancer
, 115
(12)
pp. 1479-1486.
10.1038/bjc.2016.365.
|
|
Rane, Jayant K;
Frankell, Alexander M;
Weeden, Clare E;
Swanton, Charles;
(2023)
Clonal Evolution in Healthy and Premalignant Tissues: Implications for Early Cancer Interception Strategies.
Cancer Prevention Research
, 16
(7)
pp. 369-378.
10.1158/1940-6207.CAPR-22-0469.
|
|
Ray-Coquard, I;
Trama, A;
Seckl, MJ;
Fotopoulou, C;
Pautier, P;
Pignata, S;
Kristensen, G;
... RARECARENet Working Group, .; + view all
(2019)
Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting.
European Journal of Surgical Oncology
, 45
(1)
pp. 67-74.
10.1016/j.ejso.2017.09.025.
|
|
Raza, SEA;
AbdulJabbar, K;
Jamal-Hanjani, M;
Veeriah, S;
Le Quesne, J;
Swanton, C;
Yuan, Y;
(2019)
Deconvolving Convolutional Neural Network for Cell Detection.
In:
2019 IEEE 16th International Symposium on Biomedical Imaging (ISBI 2019).
(pp. pp. 891-894).
IEEE: Venice, Italy,.
|
|
|
Read, ML;
Fong, JC;
Modasia, B;
Fletcher, A;
Imruetaicharoenchoke, W;
Thompson, RJ;
Nieto, H;
... McCabe, CJ; + view all
(2017)
Elevated PTTG and PBF predicts poor patient outcome and modulates DNA damage response genes in thyroid cancer.
Oncogene
, 36
(37)
pp. 5296-5308.
10.1038/onc.2017.154.
|
|
|
Reuter, M;
Camus, MF;
Hill, MS;
Ruzicka, F;
Fowler, K;
(2017)
Evolving Plastic Responses to External and Genetic Environments.
Trends in Genetics
, 33
(3)
pp. 169-170.
10.1016/j.tig.2017.01.004.
|
|
Rockall, AG;
Barwick, TD;
Wilson, W;
Singh, N;
Bharwani, N;
Sohaib, A;
Nobbenhuis, M;
... Study Group, M; + view all
(2021)
Diagnostic accuracy of FET-PET/CT, FDG-PET/CT and diffusion-weighted MRI in detection of nodal metastases in surgically treated endometrial and cervical carcinoma.
Clinical Cancer Research
10.1158/1078-0432.ccr-21-1834.
(In press).
|
|
|
Rodday, Angie Mae;
Evens, Andrew M;
Maurer, Matthew J;
Upshaw, Jenica N;
Counsell, Nicholas;
Rossetti, Sara;
Chang, Cheryl;
... Radford, John; + view all
(2025)
An Individualized Prediction Model for Early-Stage Classic Hodgkin's Lymphoma.
NEJM Evidence
10.1056/EVIDoa2500115.
(In press).
|
|
Roddie, C;
Dias, J;
O'Reilly, MA;
Abbasian, M;
Cadinanos-Garai, A;
Vispute, K;
Bosshard-Carter, L;
... Peggs, KS; + view all
(2025)
Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion.
Blood
, Article blood.2025028790. 10.1182/blood.2025028790.
|
|
Roddie, C;
Dias, J;
O'Reilly, MA;
Abbasian, M;
Cadinanos-Garai, A;
Vispute, K;
Bosshard-Carter, L;
... Peggs, KS; + view all
(2021)
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
Journal of Clinical Oncology
10.1200/jco.21.00917.
(In press).
|
|
|
Roncalato, FT;
Berton-Rigaud, D;
O'Connell, R;
Lanceley, A;
Sehouli, J;
Buizen, L;
Okamoto, A;
... Friedlander, M; + view all
(2018)
Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
Gynecologic Oncology
, 148
(1)
pp. 36-41.
10.1016/j.ygyno.2017.10.019.
|
|
Roncolato, FT;
Joly, F;
O'Connell, R;
Lanceley, A;
Hilpert, F;
Buizen, L;
Okamoto, A;
... Friedlander, M; + view all
(2017)
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.
The Oncologist
, 22
(9)
pp. 1117-1124.
10.1634/theoncologist.2017-0047.
|
|
Roncolato, FT;
O'Connell, R;
Joly, F;
Lanceley, A;
Hilpert, L;
Buizen, L;
Okamoto, E;
... Friedlander, ML; + view all
(2020)
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(> 3) chemotherapy – the GCIG Symptom Benefit Study (SBS).
Gynecologic Oncology
, 156
(1)
pp. 45-53.
10.1016/j.ygyno.2019.10.001.
|
|
Rosenthal, R;
Cadieux, EL;
Salgado, R;
Bakir, MA;
Moore, DA;
Hiley, CT;
Lund, T;
... TRACERx consortium; + view all
(2019)
Neoantigen-directed immune escape in lung cancer evolution.
Nature
10.1038/s41586-019-1032-7.
(In press).
|
|
Rossig, C;
Pule, M;
Altvater, B;
Saiagh, S;
Wright, G;
Ghorashian, S;
Clifton-Hadley, L;
... Amrolia, PJ; + view all
(2017)
Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia.
Leukemia
, 31
pp. 1087-1095.
10.1038/leu.2017.39.
|
|
Ruers, T;
Van Coevorden, F;
Punt, CJA;
Pierie, J-PEN;
Borel-Rinkes, I;
Ledermann, JA;
Poston, G;
... and the National Cancer Research Institute Colorectal Clinical S, .; + view all
(2017)
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.
JNCI: Journal of the National Cancer Institute
, 109
(9)
, Article djx015. 10.1093/jnci/djx015.
|
|
|
Rule, S;
Cook, G;
Russell, NH;
Hunter, A;
Robinson, S;
Morley, N;
Sureda, A;
... Peggs, KS; + view all
(2019)
Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma.
British Journal of Haematology
, 184
(6)
pp. 999-1005.
10.1111/bjh.15723.
|
|
Russell, J;
Collins, A;
Fowler, A;
Karanth, M;
Saha, C;
Docherty, S;
Padayatty, J;
... Follows, GA; + view all
(2021)
Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial.
Annals of Hematology
, 100
pp. 1049-1058.
10.1007/s00277-021-04460-9.
|
|
S
|
Seckl, MJ;
Ottensmeier, CH;
Cullen, M;
Schmid, P;
Ngai, Y;
Muthukumar, D;
Thompson, J;
... Hackshaw, A; + view all
(2017)
Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR).
Journal of Clincal Oncology
, Article 2016697391. 10.1200/JCO.2016.69.7391.
|
|
|
Shah, V;
Sherborne, AL;
Johnson, DC;
Ellis, S;
Price, A;
Chowdhury, F;
Kendall, J;
... on behalf of NCRI Haematology Clinical Studies Group; + view all
(2020)
Predicting ultrahigh risk multiple myeloma by molecular profiling:
an analysis of newly diagnosed transplant eligible myeloma XI trial
patients.
Leukemia
10.1038/s41375-020-0750-z.
|
|
|
Shankar, AG;
Roques, G;
Kirkwood, AA;
Lambilliotte, A;
Freund, K;
Leblanc, T;
Hayward, J;
... Landman-Parker, J; + view all
(2017)
Advanced stage nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents: clinical characteristics and treatment outcome - a report from the SFCE & CCLG groups.
British Journal of Haematology
, 177
(1)
pp. 106-115.
10.1111/bjh.14518.
|
|
|
Sidhu, J;
Masurekar, AN;
Gogoi, MP;
Fong, C;
Ioannou, T;
Lodhi, T;
Parker, C;
... Krishnan, S; + view all
(2022)
Activity and toxicity of intramuscular 1000 iu/m² polyethylene glycol-E. coli L-asparaginase in the UKALL 2003 and UKALL 2011 clinical trials.
British Journal of Haematology
10.1111/bjh.18158.
(In press).
|
|
|
Smith, SG;
Wardle, J;
Atkin, W;
Raine, R;
McGregor, L;
Vart, G;
Morris, S;
... von Wagner, C; + view all
(2017)
Reducing the socioeconomic gradient in uptake of the NHS Bowel Cancer Screening Programme using a simplified supplementary information leaflet: a cluster-randomised trial.
BMC Cancer
, 17
, Article 543. 10.1186/s12885-017-3512-1.
|
|
|
Sng, CCT;
Wong, YNS;
Wu, A;
Ottaviani, D;
Chopra, N;
Galazi, M;
Benafif, S;
... Shaw, H; + view all
(2020)
Cancer History and Systemic Anti-Cancer Therapy Independently Predict COVID-19 Mortality: A UK Tertiary Hospital Experience.
Frontiers in Oncology
, 10
, Article 595804. 10.3389/fonc.2020.595804.
|
|
|
Solebo, Ameenat Lola;
Kellett, Salomey;
Mcloone, Eibhlin;
Petrushkin, Harry;
Gonzalez-Martin, Jose;
Ashworth, Jane;
Choi, Jessy;
... UNICORNS, Uveitis in Childhood National Cohort Study Grp; + view all
(2025)
Incidence, sociodemographic and presenting clinical features of childhood non-infectious uveitis: findings from the UK national inception cohort study.
British Journal of Ophthalmology
, 109
(8)
pp. 955-961.
10.1136/bjo-2024-326674.
|
|
|
Spanswick, VJ;
Lowe, HL;
Newton, C;
Bingham, JP;
Bagnobianchi, A;
Kiakos, K;
Craddock, C;
... Hartley, JA; + view all
(2012)
Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.
BMC Cancer
, 12
, Article 436. 10.1186/1471-2407-12-436.
|
|
|
Spicer, James;
Basu, Bristi;
Montes, Ana;
Banerji, Udai;
Kristeleit, Rebecca;
Miller, Rowan;
Veal, Gareth JJ;
... Karagiannis, Sophia NN; + view all
(2023)
Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial.
Nature Communications
, 14
(1)
, Article 4180. 10.1038/s41467-023-39679-9.
|
|
Spiro, SG;
Hackshaw, A;
(2015)
Research in progress—LungSEARCH: a randomised controlled trial of surveillance for the early detection of lung cancer in a high-risk group.
Thorax
, 71
pp. 91-93.
10.1136/thoraxjnl-2015-207433.
|
|
Spiro, SG;
Shah, PL;
Rintoul, RC;
George, J;
Janes, S;
Callister, M;
Novelli, M;
... Hackshaw, A; + view all
(2019)
Sequential screening for lung cancer in a high-risk group: randomised controlled trial.
European Respiratory Journal
, 54
(4)
, Article 1900581. 10.1183/13993003.00581-2019.
|
|
Stark, D;
Cook, A;
Brown, J;
Brundage, M;
Embleton, A;
Kaplan, R;
Raja, F;
... Ledermann, J; + view all
(2017)
Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.
Cancer
, 123
(14)
pp. 2752-2761.
10.1002/cncr.30657.
|
|
Steptoe, A;
Hamer, M;
O'Donnell, K;
Venuraju, S;
Marmot, MG;
Lahiri, A;
(2010)
Socioeconomic Status and Subclinical Coronary Disease in the Whitehall II Epidemiological Study.
PLOS ONE
, 5
(1)
, Article e8874. 10.1371/journal.pone.0008874.
|
|
|
Szlosarek, PW;
Steele, JP;
Nolan, L;
Gilligan, D;
Taylor, P;
Spicer, J;
Lind, M;
... Hackshaw, A; + view all
(2017)
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma A Randomized Clinical Trial.
JAMA Oncology
, 3
(1)
pp. 58-66.
10.1001/jamaoncol.2016.3049.
|
T
|
Tan, WS;
Feber, A;
Dong, L;
Sarpong, R;
Rezaee, S;
Rodney, S;
Khetrapal, P;
... Kelly, JD; + view all
(2017)
DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells.
BMC Cancer
, 17
, Article 767. 10.1186/s12885-017-3758-7.
|
|
|
Tan, WS;
Feber, A;
Sarpong, R;
Khetrapal, P;
Rodney, S;
Jalil, R;
Mostafid, H;
... Kelly, JD; + view all
(2018)
Who Should Be Investigated for Haematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients.
European Urology
, 74
(1)
pp. 10-14.
10.1016/j.eururo.2018.03.008.
|
|
Tan, WS;
Sarpong, R;
Khetrapal, P;
Rodney, S;
Mostafid, H;
Cresswell, J;
Hicks, J;
... DETECT I trial collaborators; + view all
(2018)
Can renal and bladder ultrasound replace CT urogram in patients investigated for microscopic hematuria?
The Journal of Urology
, 200
(5)
10.1016/j.juro.2018.04.065.
|
|
|
Tan, WS;
Sarpong, R;
Khetrapal, P;
Rodney, S;
Mostafid, H;
Cresswell, J;
Watson, D;
... DETECT I trial collaborators, .; + view all
(2018)
Does urinary cytology have a role in haematuria investigations?
BJU International
10.1111/bju.14459.
|
|
|
Tan, WS;
Teo, CH;
Chan, D;
Ang, KM;
Heinrich, M;
Feber, A;
Sarpong, R;
... DETECT II trial collaborators, .; + view all
(2020)
Exploring patients’ experience and perception of being diagnosed with bladder cancer: A mixed methods approach.
BJU International
, 125
(5)
pp. 669-678.
10.1111/bju.15008.
|
|
|
Tan, WS;
Teo, CH;
Chan, D;
Heinrich, M;
Feber, A;
Sarpong, R;
Allan, J;
... DETECT II trial collaborators; + view all
(2019)
Mix methods approach to explore patients' perspectives on the acceptability of a urinary biomarker test in replacement of cystoscopy in bladder cancer surveillance.
BJU International
, 124
(3)
pp. 408-417.
10.1111/bju.14690.
|
|
|
Taylor, A;
Sundar, SS;
Bowen, R;
Clayton, R;
Coleridge, S;
Fotopoulou, C;
Ghaem-Maghami, S;
... Morrison, J; + view all
(2021)
British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic.
International Journal of Gynecologic Cancer
10.1136/ijgc-2021-002942.
(In press).
|
|
|
Tisi, Sophie;
Dickson, Jennifer L;
Horst, Carolyn;
Quaife, Samantha L;
Hall, Helen;
Verghese, Priyam;
Gyertson, Kylie;
... SUMMIT Consortium; + view all
(2022)
Detection of COPD in the SUMMIT Study Lung Cancer Screening Cohort using Symptoms and Spirometry.
European Respiratory Journal
, 60
(6)
, Article 2200795. 10.1183/13993003.00795-2022.
|
|
Tjokrowidjaja, A;
Friedlander, M;
Lord, SJ;
Asher, R;
Rodrigues, M;
Ledermann, JA;
Matulonis, UA;
... Lee, CK; + view all
(2021)
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy.
European Journal of Cancer
, 154
pp. 190-200.
10.1016/j.ejca.2021.06.024.
|
|
Tjokrowidjaja, A;
Lee, CK;
Friedlander, M;
Gebski, V;
Gladieff, L;
Ledermann, J;
Penson, R;
... Pujade-Lauraine, E; + view all
(2020)
Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.
European Journal of Cancer
, 139
pp. 59-67.
10.1016/j.ejca.2020.08.021.
|
|
Townsend, W;
Johnson, RJ;
Pottinger, BT;
Counsell, N;
Smith, P;
Chadwick, H;
Evans, K;
... Rudin, CE; + view all
(2016)
A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320.
Leukemia & Lymphoma
, 57
(9)
pp. 2232-2234.
10.3109/10428194.2015.1133814.
|
|
Townsend, W;
Leong, S;
Hoskin, P;
Diez, P;
Patrick, P;
Linch, D;
Wong, W-L;
... Ardeshna, K; + view all
(2019)
Treatment of classical Hodgkin lymphoma in young adults aged 18-30 years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRUK/08/012).
British Journal of Haematology
10.1111/bjh.16296.
(In press).
|
|
|
Turajlic, S;
Litchfield, K;
Xu, H;
Rosenthal, R;
McGranahan, N;
Reading, JL;
Wong, YNS;
... Swanton, C; + view all
(2017)
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.
The Lancet Oncology
, 18
(8)
pp. 1009-1021.
10.1016/S1470-2045(17)30516-8.
|
|
U
|
UK CLL Forum;
(2016)
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.
Haematologica
, 101
(12)
pp. 1563-1572.
10.3324/haematol.2016.147900.
|
|
|
Urkmez, E;
Andac-Jones, E;
Cibula, D;
Querleu, D;
Halaska, MJ;
Driak, D;
Sehouli, J;
... Gultekin, M; + view all
(2019)
Perceptions, expectations, and experiences of gynecological cancer patients: a pan-European ESGO-ENGAGe survey.
International Journal of Gynecological Cancer
, 29
(9)
pp. 1425-1430.
10.1136/ijgc-2019-000567.
|
|
V
|
Valle, JW;
Wasan, H;
Lopes, A;
Backen, AC;
Palmer, DH;
Morris, K;
Duggan, M;
... Bridgewater, JA; + view all
(2015)
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.
Lancet Oncology
, 16
(8)
pp. 967-978.
10.1016/S1470-2045(15)00139-4.
|
|
Valle-Inclan, Jose Espejo;
De Noon, Solange;
Trevers, Katherine;
Elrick, Hillary;
van Belzen, Ianthe AEM;
Zumalave, Sonia;
Sauer, Carolin M;
... Cortes-Ciriano, Isidro; + view all
(2025)
Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution.
Cell
, 188
(2)
pp. 352-370.
10.1016/j.cell.2024.12.005.
|
|
|
Vargas, FA;
Furness, AJS;
Litchfield, K;
Joshi, K;
Rosenthal, R;
Ghorani, E;
Solomon, I;
... Quezada, SA; + view all
(2018)
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Cancer Cell
, 33
(4)
pp. 649-663.
10.1016/j.ccell.2018.02.010.
|
|
|
Vargas, FA;
Furness, AJS;
Solomon, I;
Joshi, K;
Mekkaoui, L;
Lesko, MH;
Rota, EM;
... Quezada, SA; + view all
(2017)
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
Immunity
, 46
(4)
pp. 577-586.
10.1016/j.immuni.2017.03.013.
|
|
|
Veiga, C;
Landau, D;
Devaraj, A;
Doel, T;
White, J;
Ngai, Y;
Hawkes, D;
(2018)
Novel CT-based objective imaging biomarkers of long term radiation-induced lung damage.
International Journal of Radiation Oncology - Biology - Physics
, 102
(4)
10.1016/j.ijrobp.2018.06.006.
|
|
Veiga, C;
Landau, D;
McClelland, JR;
Ledermann, JA;
Hawkes, D;
Janes, SM;
Devaraj, A;
(2018)
Long term radiological features of radiation-induced lung damage.
Radiotherapy and Oncology
, 126
(2)
pp. 300-306.
10.1016/j.radonc.2017.11.003.
|
|
Vergote, I;
Gonzalez-Martin, A;
Lorusso, D;
Gourley, C;
Mirza, MR;
Kurtz, JE;
Okamoto, A;
... Zhu, J; + view all
(2022)
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
The Lancet Oncology
, 23
(8)
e374-e384.
10.1016/S1470-2045(22)00139-5.
|
|
Vergote, I;
Coens, C;
Nankivell, M;
Kristensen, GB;
Parmar, MKB;
Ehlen, T;
Jayson, GC;
... MRC CHORUS study investigators, .; + view all
(2018)
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Lancet Oncology
, 19
(12)
pp. 1680-1687.
10.1016/S1470-2045(18)30566-7.
|
|
Vesely, Clare;
Wong, Yien Ning Sophia;
Childs, Alexa;
Akarca, Ayse U;
Dhami, Pawan;
Vaikkinen, Heli;
Conde, Lucia;
... Meyer, Tim; + view all
(2022)
Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumours.
Clinical Cancer Research
10.1158/1078-0432.CCR-21-4203.
(In press).
|
|
|
Vesely, C;
Childs, A;
Wong, YNS;
Ogunbiyi, O;
Gander, A;
Luong, T;
Thirlwell, C;
... Meyer, T; + view all
(2018)
Systematic Evaluation of the Immune Microenvironment of Neuroendocrine Tumors (NET).
Presented at: 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain.
|
|
Vivekanandan, S;
Fenwick, JD;
Counsell, N;
Panakis, N;
Stuart, R;
Higgins, GS;
Hawkins, MA;
(2021)
Associations between cardiac irradiation and survival in patients with non-small cell lung cancer: Validation and new discoveries in an independent dataset.
Radiotherapy and Oncology
, 165
pp. 119-125.
10.1016/j.radonc.2021.10.016.
|
|
Vivekanandan, S;
Landau, DB;
Counsell, N;
Warren, DR;
Khwanda, A;
Rosen, SD;
Parsons, E;
... Fenwick, JD; + view all
(2017)
The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer.
International Journal of Radiation Oncology Biology Physics
, 99
(1)
pp. 51-60.
10.1016/j.ijrobp.2017.04.026.
|
|
W
|
Wald, Nicholas J;
Duffy, Stephen W;
Hackshaw, Allan;
(2024)
Risk stratification in medical screening.
Journal of Medical Screening
10.1177/09691413241255623.
(In press).
|
|
Wald, Nicholas J;
Duffy, Stephen W;
Hackshaw, Allan;
(2023)
The Risk-Screening Converter.
Journal of Medical Screening
, 30
(1)
pp. 1-2.
10.1177/09691413221149640.
|
|
Wald, Nicholas J;
Duffy, Stephen W;
Hackshaw, Allan;
(2022)
When alternatives to screening should be the priority.
Journal of Medical Screening
, Article ARTN 09691413221102322. 10.1177/09691413221102322.
(In press).
|
|
Walf-Vorderwülbecke, V;
Pearce, K;
Brooks, T;
Hubank, M;
Van den Heuvel-Eibrink, MM;
Zwaan, CM;
Adams, S;
... Williams, O; + view all
(2018)
Targeting acute myeloid leukemia by drug-induced c-MYB degradation.
Leukemia
, 32
pp. 882-889.
10.1038/leu.2017.317.
|
|
Wall, EC;
Wu, M;
Harvey, R;
Kelly, G;
Warchal, S;
Sawyer, C;
Daniels, R;
... Bauer, DL; + view all
(2021)
AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC.
The Lancet
10.1016/S0140-6736(21)01462-8.
(In press).
|
|
|
Wall, EC;
Wu, M;
Harvey, R;
Kelly, G;
Warchal, S;
Sawyer, C;
Daniels, R;
... Bauer, DLV; + view all
(2021)
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.
The Lancet
10.1016/s0140-6736(21)01290-3.
(In press).
|
|
|
Wardle, J;
von Wagner, C;
Kralj-Hans, I;
Halloran, SP;
Smith, SG;
McGregor, LM;
Vart, G;
... Raine, R; + view all
(2016)
Effects of evidence-based strategies to reduce the socioeconomic gradient of uptake in the English NHS Bowel Cancer Screening Programme (ASCEND): four cluster-randomised controlled trials.
The Lancet
, 387
(10020)
pp. 751-759.
10.1016/S0140-6736(15)01154-X.
|
|
Waterhouse, JV;
Hull, JH;
Linch, M;
(2020)
Corticosteroids for Urological Cancer Care During Coronavirus Disease 2019. Treat or Not to Treat?
European Urology
10.1016/j.eururo.2020.04.027.
(In press).
|
|
|
Watkins, Rachel J;
Imruetaicharoenchoke, Waraporn;
Read, Martin L;
Sharma, Neil;
Poole, Vikki L;
Gentilin, Erica;
Bansal, Sukhchain;
... McCabe, Christopher J; + view all
(2016)
Pro-invasive Effect of Proto-oncogene PBF Is Modulated by an Interaction with Cortactin.
The Journal of Clinical Endocrinology & Metabolism
, 101
(12)
pp. 4551-4563.
10.1210/jc.2016-1932.
|
|
|
Watkins, Thomas Benjamin Kingdon;
(2020)
The role of chromosomal instability and parallel evolution in cancer.
Doctoral thesis (Ph.D), UCL (University College London).
|
|
Watts, C;
Ashkan, K;
Jenkinson, MD;
Price, SJ;
Santarius, T;
Matys, T;
Zhang, TT;
... Counsell, N; + view all
(2021)
An evaluation of the tolerability and feasibility of combining 5-amino-levulinic acid (5-ala) with bcnu wafers in the surgical management of primary glioblastoma.
Cancers
, 13
, Article 3241. 10.3390/cancers13133241.
|
|
|
Webster, AK;
Hung, A;
Moore, BT;
Guzman, R;
Jordan, JM;
Kaplan, REW;
Hibshman, JD;
... Baugh, LR; + view all
(2019)
Population Selection and Sequencing of Caenorhabditis elegans Wild Isolates Identifies a Region on Chromosome III Affecting Starvation Resistance.
G3
, 9
(10)
pp. 3477-3488.
10.1534/g3.119.400617.
|
|
|
Wheeler, G;
Pallmann, P;
Wan, F;
Mander, A;
Yap, C;
Clive, S;
Hampson, L;
(2019)
Designing and evaluating dose-escalation studies made easy: the MoDEsT web app.
Clinical Trials
10.1177/1740774519890146.
(In press).
|
|
|
Wheeler, GM;
(2016)
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach.
Statistical Papers
pp. 1-11.
10.1007/s00362-016-0790-7.
|
|
Wheeler, GM;
Mander, A;
Bedding, A;
Brock, K;
Cornelius, V;
Grieve, A;
Jaki, T;
... Bond, S; + view all
(2019)
How to design a dose-finding study using the Continual Reassessment Method.
BMC Medical Research Methodology
, 19
, Article 18. 10.1186/s12874-018-0638-z.
|
|
|
Wheeler, GM;
Mander, A;
Yap, C;
(2018)
Practical implementation of dose-response adaptive trials.
In:
Wiley Statsref: Statistics Reference Online.
Wiley: Hoboken, NJ, USA.
|
|
Wheeler, GM;
Sweeting, M;
Mander, A;
(2019)
A Bayesian model‐free approach to combination therapy phase I trials using censored time‐to‐toxicity data.
Journal of the Royal Statistical Society: Series C (Applied Statistics)
, 68
(2)
pp. 309-329.
10.1111/rssc.12323.
|
|
Wheeler, GM;
Sweeting, MJ;
Mander, AP;
(2017)
Toxicity-dependent feasibility bounds for the Escalation with Overdose Control approach in phase I cancer trials.
Statistics in Medicine
, 36
(16)
pp. 2499-2513.
10.1002/sim.7280.
|
|
|
Wheeler, GM;
Sweeting, MJ;
Mander, AP;
(2016)
AplusB: A Web Application for Investigating A plus B Designs for Phase I Cancer Clinical Trials.
PLOS ONE
, 11
(7)
, Article e0159026. 10.1371/journal.pone.0159026.
|
|
|
Wheeler, GM;
Sweeting, MJ;
Mander, AP;
Lee, SM;
Cheung, YKK;
(2017)
Modelling semi-attributable toxicity in dual-agent phase I trials with non-concurrent drug administration.
Statistics in Medicine
, 36
(2)
pp. 225-241.
10.1002/sim.6912.
|
|
|
Whelan, J;
Hackshaw, A;
McTiernan, A;
Grimer, R;
Spooner, D;
Bate, J;
Ranft, A;
... Lewis, I; + view all
(2018)
Survival is influenced by approaches to local treatment of Ewing sarcoma within an international randomised controlled trial: analysis of EICESS-92.
Clinical Sarcoma Research
, 8
, Article 6. 10.1186/s13569-018-0093-y.
|
|
|
Willis, SE;
Winkler, C;
Roudier, MP;
Baird, T;
Marco-Casanova, P;
Jones, E;
Rowe, P;
... Jones, GN; + view all
(2021)
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
British Journal of Cancer
10.1038/s41416-021-01560-1.
|
|
|
Wilson, MR;
Eyre, TA;
Kirkwood, AA;
Wong Doo, N;
Soussain, C;
Choquet, S;
Martinez-Calle, N;
... McKay, P; + view all
(2022)
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.
Blood
, 139
(16)
pp. 2499-2511.
10.1182/blood.2021014506.
|
|
Wilson, MR;
Kirkwood, AA;
Wong Doo, N;
Soussain, C;
Choquet, S;
Lees, C;
Fox, C;
... Eyre, TA; + view all
(2024)
Dosage of high-dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse.
American Journal of Hematology
, 99
(2)
E46-E50.
10.1002/ajh.27167.
|
   |
|
Wilson, GA;
Feil, EJ;
Lilley, AK;
Field, D;
(2007)
Large-scale comparative genomic ranking of taxonomically restricted genes (TRGs) in bacterial and archaeal genomes.
PLoS One
, 2
(3)
, Article e324. 10.1371/journal.pone.0000324.
|
|
|
Wong, Yien Ning Sophia;
(2021)
Identification of urine derived lymphocytes as a non-invasive measure of the tumour immune microenvironment in bladder cancer.
Doctoral thesis (Ph.D), UCL (University College London).
|
|
Wong, YNS;
Sng, CCT;
Ottaviani, D;
Patel, G;
Chowdhury, A;
Earnshaw, I;
Sinclair, A;
... Lee, AJX; + view all
(2021)
Systemic anti-cancer therapy and metastatic cancer are independent mortality risk factors during two uk waves of the covid-19 pandemic at university college london hospital.
Cancers
, 13
(23)
, Article 6085. 10.3390/cancers13236085.
|
|
|
Wong, YNS;
Joshi, K;
Khetrapal, P;
Ismail, M;
Reading, JL;
Sunderland, MW;
Georgiou, A;
... Quezada, SA; + view all
(2018)
Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment.
Journal of Experimental Medicine
, 215
(11)
pp. 2748-2759.
10.1084/jem.20181003.
|
|
|
Wong, YNS;
Joshi, K;
Pule, M;
Peggs, KS;
Swanton, C;
Quezada, SA;
Linch, M;
(2017)
Evolving adoptive cellular therapies in urological malignancies.
Lancet Oncology
, 18
(6)
E341-E353.
10.1016/S1470-2045(17)30327-3.
|
|
|
Wood, GE;
Ledermann, JA;
(2022)
Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer.
Best Practice & Research Clinical Obstetrics & Gynaecology
, 78
pp. 64-73.
10.1016/j.bpobgyn.2021.09.002.
|
|
Wu, Yin;
Biswas, Dhruva;
Usaite, Ieva;
Angelova, Mihaela;
Boeing, Stefan;
Karasaki, Takahiro;
Veeriah, Selvaraju;
... Swanton, Charles; + view all
(2022)
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer.
Nature Cancer
, 3
pp. 696-709.
10.1038/s43018-022-00376-z.
|
Y
|
Yang, Z;
Hackshaw, A;
Feng, Q;
Fu, X;
Zhang, Y;
Mao, C;
Tang, J;
(2017)
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
International Journal of Cancer
, 140
(12)
pp. 2805-2819.
10.1002/ijc.30691.
|
|
Z
|
Zakeri, K;
Rotolo, F;
Lacas, B;
Vitzthum, LK;
Le, Q-T;
Gregoire, V;
Overgaard, J;
... MARCH/MACH-NC Collaborative Group and the Head and Neck Cancer I; + view all
(2020)
Predictive classifier for intensive treatment of head and neck cancer.
Cancer
, 126
(24)
pp. 5263-5273.
10.1002/cncr.33212.
|
|
Zhang, Hanyun;
AbdulJabbar, Khalid;
Moore, David A;
Akarca, Ayse;
Enfield, Katey SS;
Jamal-Hanjani, Mariam;
Raza, Shan E Ahmed;
... Yuan, Yinyin; + view all
(2023)
Spatial Positioning of Immune Hotspots Reflects the Interplay between B and T Cells in Lung Squamous Cell Carcinoma.
Cancer Research
, 83
(9)
pp. 1410-1425.
10.1158/0008-5472.CAN-22-2589.
|
|
